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ABSTRACT

CHARACTERIZING THE EFFECT OF CJUN ON THE EXPRESSION OF OCT4
VARIANTS, POTENCY AND CELL FATE OF MURINE EMBRYONIC STEM
CELLS

Kristine Teague

cJun is a transcription factor associated with proliferation and growth. Recent
evidence has shown it plays a role in cell fate decision making of embryonic stem cells
and correlates with changes in Oct4 expression, an important marker for pluripotency.
There are multiple Oct4 isoforms that arise from alternative splicing and alternative
translation. Oct4A is the variant most frequently associated with pluripotency, while
evidence suggests that Oct4B variants have roles in potency as well as stress responses.
We aimed to study the effect of cJun over expression in murine embryonic stem
cells on Oct4 gene expression through two methods: transient transfection of a pLVX
cJun plasmid and treatment with nocodazole. We hypothesized that cJun expression
would be increased with both of these methods and that these increases would affect Oct4
gene expression, which would affect the expression of the potency markers Nanog and
Sox2 and possibly the expression of germ layer markers Brachyury, Sox1, Gata6, and
Gata4. The unphosphorylatable cJun mutant L40/42A was also transfected to assess the
role of cJun transcriptional activity on these processes. Our results revealed a trend where
increased cJun correlated with changes in Oct4 variant expression that correlate with
ii

cJun transcriptional activity. Nanog expression appeared unaffected by transfection, but
decreased with nocodazole treatment. Sox2 expression appeared to increase slightly with
transfection, but remained relatively unaffected by nocodazole treatment. cJun
overexpression through transfection increased endoderm markers Gata6 and Gata4,
which correlates from other data in our laboratory that shows overexpression of cJun
increases cardiomyocyte differentiation of mES cells (Brewer 2017). Further studies will
better elucidate the relationship between cJun, the Oct4 variants, and their effect on
potency and cell fate.
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INTRODUCTION

Cellular potency is the term used to describe the ability of undifferentiated cells to
differentiate into multiple cell types. As cells become directed towards a particular cell
fate, their potency decreases. Embryonic stem cells (ESCs) are derived from the inner
cell mass (ICM) of the blastocyst and have the ability to form all the cells of the
organism, as evidenced by their ability to contribute to all the tissues of a chimeric
organism when placed into a blastocyst (Martin 1981). Therefore, they are described as
pluripotent. The pluripotency of ESCs make them useful in studying the molecular and
cellular mechanisms of organismal development and disease. Through an understanding
of these processes, cellular-based therapies can be developed to provide targeted
treatment options (reviewed in Pan et al. 2002, Romito and Cobellis 2016, Chen et al.
2017).
Cellular potency is controlled by a complex network of molecular mechanisms
that regulate gene expression, beginning with chromatin regulation. The open and varied
structures of chromatin in ESCs lead to expression of genes necessary for the pluripotent
state, in comparison to more differentiated cells (Meshorer et al. 2006, Efroni et al. 2008,
Barrero et al. 2010). Additionally, ESCs are characterized as having increased expression
of chromatin remodeling factors (Ho et al. 2009) and hypomethylated promoters which
facilitate gene expression (Grabole et al. 2013). In addition to open and active promoter
regions, expression of developmental genes, such as those involved in lineage
commitment, are regulated by bivalent promoter regions that suppress gene expression,
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while leaving the machinery poised for transcription. These regions are characterized by
H3K27me3 and H3K4me3 modifications (Azuara et al. 2006, Bernstein et al. 2006)
which are antagonistic histone modifications, the presence of CpG islands (Fouse et al.
2008, Meissner et al. 2008), and the presence of RNA polymerase II at transcription
initiation sites of many developmental genes (Guenther et al. 2007).
The three main transcription factors involved in maintaining pluripotency are
Oct4, Sox2, and Nanog (reviewed in Chambers and Smith 2004, Takahashi and
Yamanaka 2006, Okita et al. 2007, Chen et al. 2017). Generally, the three proteins work
together to regulate expression of their own genes as well as others important to
maintaining pluripotency (reviewed in Shi and Jin 2010). They also occupy many of
these bivalent regions in various combinations, which suggests that they regulate the
repression of developmental genes (Boyer et al. 2005). While these three factors are the
main transcription factors, they work in cooperation with each other, and other
transcription factors, to form a regulatory network that maintains pluripotency and selfrenewal until a developmental signal initiates a differentiation program that changes the
chromatin landscape (Wang et al. 2006, Pardo et al. 2010). Overexpression of the three
together is sufficient for reprogramming terminally differentiated cells (Takahashi and
Yamanaka 2006, Okita et al. 2007). Additionally, Oct4 is the only one which cannot be
substituted with any other member of the Octamer binding protein family (reviewed in
Jerabek et al. 2014).
The Role of Oct4 in Pluripotency and Development
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Oct4/Pou5f1 is part of the POU, or Pit-Oct-Unc, family of transcription factors
and is essential for the maintenance and self-renewal of pluripotent stem cells. The
protein consists of a POU specific DNA binding domain, POU homeodomain, and Cterminal and N-terminal transactivation domains (reviewed in Shi and Jin 2010).
Expression of the Oct4 protein is high in early development and is necessary for the
pluripotency of the ICM during the blastocyst stage, as deletion of Oct4 in embryos
during the transition from morula to blastocyst removes the ability of the embryo to
differentiate toward primitive endoderm or epiblast tissues (Le Bin et al. 2014). Not only
is Oct4 capable of actively maintaining potency through activation of potency genes, it
also plays a role in lineage commitment and development. The loss of Oct4 results in the
inability of the ICM to develop into the three germ layers required for development and
instead becomes trophectoderm tissue (Nichols et al. 1998, Velkey and Sue O ’shea
2003). Oct4 levels must be kept at specific levels to maintain potency (reviewed in Shi
and Jin 2010). A less than two-fold over expression of Oct4 can lead to differentiation
into primitive endoderm and mesoderm tissues, more specifically, derivatives of those
germ layers, such as the cardiac cell lineage in mouse ESCs and embryos in the early
stages of differentiation (Zeineddine et al. 2006, Rodriguez et al. 2007), while a reduction
of Oct4 expression by one-half leads to trophoblast tissue (Niwa et al. 2000).
A balance of enhancing and inhibiting factors function in combination with each
of the three core pluripotency transcription factors to facilitate the cell fate decision
making process that enables differentiation (Boyer et al. 2005, reviewed in Jerabek et al.
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2014). Oct4 has been shown to be a key factor this process. When Oct4 is overexpressed
in murine embryonic stem cells, it switches from the Sox2 promoter region to that of
Sox17. This results in a change in chromatin structure from one that favors pluripotency
to one that drives cells to mesoendoderm and ultimately cardiomyocyte-like cell fate
(Aksoy et al. 2013, Abboud et al. 2015). Additionally, Oct4 regulates Fgf4 signaling
which acts as a paracrine signal from ICM cells to the trophectoderm and directly
activates expression of Gata6, predisposing it toward a primitive endoderm fate
(reviewed in Jerabek et al. 2014). As a paracrine signal, Ffg4 initiates the upregulation of
Sox17 and Gata4 in progenitor cells of the primitive endoderm, but the loss of Oct4
causes a complete loss of Gata6 four days post coitum (dpc) and the Fgf4-dependent gene
expression of primitive endoderm genes is compromised and only minimally rescued
with exogenous Fgf4.
Oct4 gene expression is regulated by a GC rich, TATA-less, and hypomethylated
promoter which is critical to the maintenance and self-renewal of stem cells (Hattori et al.
2004; Feldman et al. 2006; reviewed in Hackett and Surani 2012). As it is conserved over
a number of mammalian species, regulation of its expression and how it correlates with
the stages of development has been well studied in the murine system (reviewed in
Jerabek et al. 2014). There are two enhancer elements, distal and proximal, which drive
transcription of Oct4 in a tissue and developmentally specific manner. The proximal
promoter is responsible for activity during the epiblast stage, while the distal enhancer
functions prior to implantation and is then restricted to germ cell lineages following
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implantation (reviewed in Jerabek et al. 2014). Multiple transcription factor proteins
directly bind the Oct4 promoter to control its transcription and external factors such as
leukemia inhibitory factor (LIF), Wingless-related integration site (Wnt), and TGFβ/bone morphogenic protein (BMP) signaling influence Oct4 expression. BMP works
with LIF synergistically to maintain potency through activation of the JAK/STAT3 and
phosphophatidylinositol 3-kinase (PI3K)/ AKT signal pathways to activate Oct4
transcription (reviewed in Jerabek et al. 2014). Oct4 transcription can also be increased
through Wnt/ β-catenin signaling, which activates the TCF/LEF complex bound at three
specific sequences in the Oct4 promoter (Li et al. 2012). Examples of other molecules
that regulate Oct4 transcription include steroidogenic factor-1, estrogen-related receptor b
(Esrrb), Sall4, Tcf3, HIF, CDK2, and germ cell nuclear factor (GNFC) (reviewed in Shi
and Jin 2010 and Jerabek et al. 2014).
Oct4 activity is also regulated through mRNA splicing and alternative translation.
The human OCT4 gene, POU5F1, can produce 3 different mRNAs through alternative
splicing: OCTA, OCTB and OCT4B1. OCT4A is the main variant involved in
pluripotency and typically expressed at higher levels than OCT4B in nuclei of pluripotent
cells (reviewed in Wang and Dai 2010 and Jerabek et al. 2014). The OCT4B splice
variant contains an internal ribosomal entry site (IRES) and a different start codon that
allows it to produce 3 different gene products through alternative translation: OC4B-265,
OCT4B-190 and OCT4B-164. These variants only differ in their N-terminal
transactivation domains: OCT4B-190 and -164 do not have N-terminal transactivation
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domains and OCT4-265 has a domain that differs from OCT4A. All of the OCT4B
isoforms have a nuclear localization signal, however they tend to localize in the
cytoplasm. OCT4B-190 appears to respond to heat and cell stress and its overexpression
protects against apoptosis following heat shock, while OCT4B-265 increases with
genotoxic stress and is correlated with an increase in apoptosis (reviewed in Jerabek et al.
2014). The OCT4B1 variant is a putative stemness marker, because its expression pattern
is high in undifferentiated cells and decreases upon differentiation, mimicking OCT4A
expression throughout development (Atlasi et al. 2008, Papamichos et al. 2009). This was
demonstrated in 59 human ESC lines as well as a significant correlation with NANOG
expression in undifferentiated cells and a strong negative correlation to genes upregulated
upon differentiation (Atlasi et al. 2008, Papamichos et al. 2009).
The mouse Oct4 homologue also produces Oct4A and Oct4B transcripts through
alternative splicing. Cells in the neuroblastic layer of mice were found to express these
Oct3/4 variants and to have both stem cell-like characteristics and those of differentiated
neurons, providing a case for Oct4 expression in somatic tissues (Mizuno and Kosaka
2008). Oct4B can be translated into multiple isoforms: Oct4B-247aa, Oct4B-190aa and
Oct4B-164aa (Guo et al. 2012). Mouse Oct4B is very similar to the human OCT4B.
Oct4B localizes in the cytoplasm, increases expression upon heat shock or oxidative
stress and many of the amino acids in the N-terminal domain are identical to the human
OCT4B N-terminal domain. The expression of various isoforms appears to correlate to
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different environmental and developmental functions, however Oct4A seems to have a
larger role in development and pluripotency.

Figure 1. Mouse Oct4 produces two mRNA transcripts (A.) and four protein
isoforms (B. and C.). These figures were originally published in Guo et. al 2012.

More recently Liu et al. have demonstrated new transcript and protein variants in
mouse Oct4B (2017). They observed the same Oct4A and Oct4B transcripts seen
previously, with the addition of four other transcript variants (Figure 2). These new
Oct4B mRNAs vary in the number and size of introns retained. Oct4B and Oct4B’ differ
in the number of nucleotides spliced out of intron 1, while the remaining variants contain
intron 2 (Oct4B1), introns 2 and 4 (Oct4B2), or introns 2 through 4 (Oct4B3). Because
NIH3T3 cells do not produce endogenous Oct4 variants, protein variants were assessed
through transient transfection with four constructs: Oct4b (pOb), Oct4b’ (pOb’), Oct4b2
(pOb2), and Oct4b3 (pOb3). Protein analysis after 36 hours post transfection showed that
Oct4b’ produced one 189aa band, while the others produced three bands: Oct4B-246aa, 221aa and -189aa (Figure 2). Interestingly, these three bands are produced for Oct4b2
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and 3 despite premature stop codons. Additionally, the 163aa product previously
described by Mizuno and Kosaka (2008) was not seen in this study.
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A.

B.

C.

Figure 2: Mouse Oct4 produces six mRNA transcripts and multiple protein
products. A. Analysis of mouse chromosomal 17 sequence shows the different exons
for each variant in color and indicated by the bars to the right of the sequence. Oct4A
mRNA consists of exon 1-5 with text in blue. The beginning sequence for Oct4b is
highlighted in red text and the beginning of Oct4b’ is highlighted in purple text. All
exons and variants can also be determined by the bars to the right of the sequence. B. A
graphical representation of the six mRNA transcripts. C. Western blot analysis of
Oct4B protein from transiently transfected NIH3T3. Oct4b’ (pOb’)constructs produced
one band at 189aa, while Oct4b (pOb), Oct4b2 (pOb2), and Oct4b3 (pOb3) each
produce three bands at 189aa, 221aa, and 246aa (Liu et al. 2017).
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Regulation of Oct4 Expression Through c-Jun

cJun is a dimeric transcription factor belonging to the activator protein 1 (AP-1)
family. An immediate early gene, transcription of cJun is increased by mitogen
stimulation (reviewed in Curran and Franza 1988). The transcriptional activity of cJun is
increased through phosphorylation of serine-63 and serine-73 (reviewed in Shaulian and
Karin 2002, Czaja 2003) primarily performed by mitogen activated protein kinase
(MAPK) family member Jun N-terminal kinase (JNK) (reviewed in Shaulian and Karin
2002 and Eferl and Wagner 2003). cJun expression can also be increased through
alternative translation pathways activated through cytoskeletal disrupting drugs such as
nocodazole (Polak et al. 2006, Blau et al. 2012). Nocodazole increases cJun protein
expression in cell culture, but this is independent of mitogen activation and does not
increase cJun transcript levels (Polak et al. 2006). Rather, the alternative translation of
cJun was shown to be regulated by an IRES in the cJun 5’ UTR (Polak et al. 2006).
cJun has been shown to provide a variety of functions during cellular cycling and
development. It regulates cellular progression from G to S1 of the cell cycle, apoptosis,
and oncogenic transformation (reviewed in Jochum et al. 2001and Shaulian and Karin
2002). Additionally, cJun plays a role in development. cJun deficient mice, which contain
a mutation in the cJun locus, die 11-12 days post coitum (dpc) (Johnson et al. 1993) and
these fetuses present with defects in the interventricular septum of the heart and
incomplete separation of aorta and pulmonary artery, suggesting lethality is a result of
impaired cardiovascular function (Eferl et al. 1999). cJun deficient ESCs were able to
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contribute to all tissues in a chimeric mouse, except for the liver (Hilberg et al. 1993) and
cJun deficient fetal hepatocytes have an increased incidence of apoptosis and decreased
proliferation (Eferl et al. 1999). Loss of cJun in hepatocytes, postnatally, did not result in
any abnormalities other than impaired regeneration following a partial hepatectomy
(Behrens et al. 2002). cJun was also expressed almost ubiquitously throughout
development, however heightened expression was noted within rapidly dividing cells
(Wilkinson et al. 1989). A more recent study showed cJun expression promoted axon
growth in central nervous system neurons, independently of other target genes thought to
be essential for cJun to promote axon growth (Lerch et al. 2014). It has also been
demonstrated that cJun inhibits the expression of potency genes such as Nanog, Sall4,
and Oct4 in mouse embryonic stem cells, while upregulating genes that lead to endoderm
lineage like Gata6 and Gata4 (Liu et al. 2015).
cJun transcriptional activity can regulate Oct4 transcription and transient
expression of cJun has shown a decrease in pluripotency in mESCs (Liu et al. 2015,
Veluscek et al. 2016, Hosawi et al. in prep). Our lab has located a putative AP-1 binding
site within the proximal promoter of the Oct4 gene. Using a polyclonal antibody
generated from the first 138 amino acids of the human Oct 4 protein, we have shown an
increase in endogenous phosphorylated cJun. This correlates with an increase in protein
containing amino acids from the Oct4A and Oct4B isoforms in murine embryonic stem
cells (mES) cells treated with anisomycin, a JNK activator, or transfected with a GFP
cJun construct (Hosawi 2016). Overexpression of cJun in mES cells prevented the
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formation of insulin secreting clusters (Hosawi 2016), increased Gata4 protein
expression, and correlated with increased cardiomyocyte differentiation (Brewer 2017).
Our lab also demonstrated that cJun can up-regulate transcription of the Oct4 promoter
through luciferase assays (Brewer 2017). Chromatin immunoprecipitation data shows
cJun physically associates with the Oct4 promoter (Varkey unpublished data). In light of
these data, we are interested in determining whether cJun can affect Oct4 variant
expression and if that affects the expression patterns of genes involved in murine
embryonic stem cell potency and cell fate decision making required in early embryonic
development.
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Figure 3. Immunoblot of nuclear protein from cells treated with SP600125,
Anisomycin, and nocodazole. A. Following nocodazole treatment for 2h and
4h, cJun protein expression is increased. While Oct4A expression also increases
upon treatment with nocodazole for 2h and 4h, Oct4all protein expression shows
little change. B. Immunoblot data for a different replicate which shows an
increase in cJun following 2h treatment with nocodazole, however no changes in
cJun expression are seen at 4h. Additionally, Oct4all and Oct4A expression do
not appear to change drastically, despite the differences in cJun expression at 2h
and 4h.
Statement of Aims

This project aims to elucidate the role of cJun in regulating Oct4 expression and
its effects on the regulation of genes involved in pluripotency and early embryonic
development. Data generated by others in our lab with an Oct4 variant-specific antibody
suggested that cJun increased expression of the Oct4A and Oct4B, however it remains
unclear whether this occurs at the transcriptional or translational control. If
overexpression of cJun changes the expression of Oct4 in murine embryonic stem cells,
we predict cell fate decision making could be affected. Finally, it is unknown if

14
cytoskeletal-induced translation of cJun occurs in murine embryonic stem cells and, if so,
whether or not this mechanism affects Oct4 transcription and/or protein expression. We
intend to address these questions through the following aims:
Specific Aim #1: Define the role of cJun in the regulation of mRNA expression of Oct4
and other pluripotency genes.
In order to test if cJun affects Oct4 expression at the transcriptional level, we have
characterized the levels of Oct4 mRNA in mES cells that were transiently transfected
with GFP cJun, the transcriptionally inactive cJun mutant GFP cJun L40/42A, and GFP
alone. RNA was isolated from these cells, reverse transcribed to cDNA and screened by
qPCR to see if there was a change in the transcript levels of Oct4A by using primers
designed to amplify exon 1. We amplified Oct4B variants using primers for exon 2
(Oct4all_E2), which do not amplify Oct4A sequences, and all Oct4 variants using
primers for exon 5 (Oct4all_E5), which is present in all variants. Primers specific to the
GFP cJun construct, pLVXcJun primers, were designed and used to establish levels of the
ectopically expressed cJun mRNA above that of endogenous cJun ( Appendix B). The
expression of each gene was normalized to Gapdh and compared, using relative
quantification, for each sample: no treatment (NT), empty vector (GFP), and a
transcriptionally inactive cJun (L40/42) controls, as well as the GFP cJun overexpression
construct. Because we have previously demonstrated that an increase in cJun correlates to
an increase in a mixed pool of protein containing Oct4A, Oct4B or Oct4B1, we expected
to see an increase in these transcripts if this correlation was transcriptionally regulated. If
increases in cJun and/or Oct4 variants change the potency of the cells, we might also see
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a modification in the mRNA levels of Sox2 and Nanog. Therefore, qPCR was used to
quantify those transcripts as well.
Specific Aim #2: Determine the effect of cJun overexpression on germ layer gene
expression
If overexpression of cJun changes the amount of Oct4 protein in murine
embryonic stem cells, we predicted the cells may be directed towards a specific cell fate.
As a specific level of Oct4 protein is necessary to maintain pluripotency or initiate
differentiation, an increase in Oct4 would lead to a change in expression of genes
associated with germ layer formation, which we assessed through RT-qPCR. The cDNA
generated from the mESCs transfected with GFP, GFP cJun, or GFP cJun L40/42A was
analyzed for the expression of germ layer markers Brachyury (mesoderm), Gata6
(endoderm), Gata4 (endoderm), and Sox1 (ectoderm). The gene expression for all genes
and each sample was normalized to Gapdh and quantified using relative quantification.
Specific Aim #3: Determine if nocodazole treatment increases cJun protein in murine
embryonic stem cells and if that increase correlates with changes in Oct4 protein
expression
Immunoblot data in our lab demonstrates the addition of nocodazole to mESCs
can increase the phosphorylation of cJun. It can also affect the levels of Oct4 protein,
however the mechanism is unknown and our result is inconsistent (Figure 3).We are
curious to know if the increased Oct4 isoforms observed are associated with the increased
expression of cJun, or if the alternative translation pathway induced through cytoskeleton
disruption would also affect Oct4 translation. As a preliminary test, we addressed the
effect of nocodazole on Oct4 levels through RT-qPCR and immunocytochemistry (ICC)
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assays. Cells were previously treated with nocodazole for two hours and stored for later
RNA extraction. RNA was extracted from nocodazole treated cells, NT, and DMSO
controls and evaluated for changes in the Oct4 transcript. In addition, mESCs were
treated with nocodazole and stained for cJun, Oct4 and Oct4A/B. While by no means a
conclusive test, if increased cJun expression co-localizes with increased Oct4A
expression, that would support a hypothesis that cJun overexpression is related to Oct4
expression.
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METHODS

Basic Cell Culture of J1 Murine Embryonic Stem Cells

Murine Embryonic cell line J1 (American Type Culture Collection (ATCC) (Cat#
SCRC1010, Manassas, VA) were grown on a feeder layer of murine embryonic

fibroblasts treated with mitomycin C (MEFs, CytoSpring LLC, Mountain View, CA) and
plated at 30,000 cells/cm2 in culture dishes that have been pre-treated with a 0.1% gelatin
solution (STEMCELL Technologies Inc, Vancouver, BC, Canada). Prior to mESC plating,

these MEFs were incubated in MEF media consisting of 10% fetal bovine serum (Life
Technologies, Carlsbad, CA) in 1X DMEM base media (Life Technologies, Carlsbad,
CA). Mouse ESCs were grown in mESC media containing DMEM, 15% FBS, 1%
2.0mM L-Alanyl-L-glutamine (STEMCELL Technologies Inc, Vancouver, BC, Canada),
0.1 mM 2-mercaptoethanol (Sigma- Aldrich, Louis, MO), 1% 1X nonessential amino
acids (Life Technologies, Carlsbad, CA), and 50 units/ml LIF (EMD Millipore, Temecula,
CA). All cells were incubated at 37℃ and 5% CO2 and passaged at approximately 50%

confluency. Each time cells were passaged, cells were washed with sterile DPBS (Life
Technologies, Carlsbad, CA), treated with 0.05% trypsin to remove adhered cells, spun
down at 1400 x g for 5 minutes at room temperature and resuspended in warmed fresh
mESC media. Cells were quantified and viability assessed with a trypan blue assay and
all cells were plated at 30,000cells/cm2.
.
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Immunocytochemistry

MEFs were plated to glass coverslips coated in 2 μg/ml fibronectin (SigmaAldrich, Louis, MO) and incubated in MEF media described above until mESC plating.

mESCs were plated on MEF coated coverslips at 30,000 cells/cm2 and incubated in
mESC media at 37℃ and 5% CO2 for 48h. Following this incubation, cells were treated
with nocodazole at a final concentration of 5µg/ml or a 0.1% DMSO control for 2 or 4
hours. After drug treatment, cells were rinsed with DPBS and fixed in 0.5ml 4%
paraformaldehyde in PBS per well for 5 minutes at room temperature. After fixation, the
cells were washed five times in two-minute incubations with DPBS. The cells were then
permeabilized with 2 ml of 1% NP-40 (Sigma- Aldrich, Louis, MO) in DPBS in each well
and incubated at room temperature for 30 minutes. Next, blocking buffer containing
1.0% normal goat serum (Thermo Fisher Scientific, Waltham, MA) and 0.1% TX-100
(Sigma- Aldrich, Louis, MO) in DPBS was added to each well and incubated at room

temperature for 30 minutes. The first primary antibody was added to their respective
wells (Table 1): Anti-cJun (Abcam119944), Anti-Oct4 (Abcam ab19857) or Anti-Oct4A
(Cell Signaling Technologies 2840S). A no primary control coverslip was treated with
blocking solution instead of primary antibody and these cells were incubated at room
temperature for 1h. The coverslips were washed three times, for 5 minutes each, with
DPBS and the appropriate secondary antibody listed in Table 1 was added at the
appropriate dilution to each well and incubated for 60 minutes at room temperature, in
the dark. Coverslips were washed three times with DPBS, five minutes each, in the dark

19
and then placed back in block solution and incubated in the dark at room temperature for
30 minutes. Following this incubation, the second primary antibody was added to the
appropriate wells, with block solution added to the no primary control, and incubated in
the dark at room temperature for 60 minutes. While remaining in the dark, the cells were
rinsed three times with DPBS, five minutes each, and the appropriate secondary antibody
added (Alexafluor 488 or Texas Red, Table 1) (Molecular Probes, Life Technologies,
Grand Island, NY).
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Table 1. Antibodies and dilutions used in ICC analysis. Stem cells treated with

nocodazole will be incubated with cJun and either Oct4 or Oct4A/B antibodies. This
determined the relative expression of Oct4 or Oct4A/B in reference to cJun within the
same cell.

Antibody

Company and
catalog number

Dilution

Mouse anti-cJun

Abcam1ab 19944

1/200

Rabbit anti-Oct4

Abcam ab19857

1/200

Rabbit anti-Oct4A/B

Cell Signaling

1/200

Technologies 2840S

Alexafluor 488: Goat

Life Technologies

IgG to mouse IgG

A11001

Texas Red: Goat IgG
to rabbit IgG

Life Technologies

1/500

1/200

T6391

Cells were incubated in the dark at room temperature for 60 minutes and rinsed
three times with DPBS, five minutes each. Each coverslip was then be mounted on a
glass slide with 7μl of DAPI mounting media (Molecular Probes, Life Technologies,
Grand Island, NY) and allowed to cure overnight at room temperature, covered. The

coverslips were then surrounded by nail polish, allowed to dry, and stored covered at 4°C
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for long term storage. The cells were imaged using a Zeiss Axio Observer Z1
microscope.
RNA Isolation, cDNA Generation and Quantitative PCR

RNA was isolated from several stored samples, mentioned above, according to a
protocol adapted from the Fisher Bio Reagents SurePrep TrueTotal RNA Purification Kit
(Cat# BP2800-50). Briefly, cells were lysed with 350μl lysis solution containing betamercaptoethanol and vortexed for 15 seconds. 200μl of 95-100% ethanol was added and
each sample vortexed for 10 seconds. The lysate solution was placed on column and
centrifuged at 14000 x g for 1 minute. The flow-through was discarded and 400μl of
wash solution was applied to the column and centrifuged at 14000 x g for 1 minute. The
flow-through was discarded and this step was repeated once more. A third wash was
done with 400μl of wash solution and spun down at 14000 x g for 2 minutes to dry the
column. The collection tube was discarded with the flow-through and the column placed
in a 1.5ml Eppendorf tube. Elution buffer (50μl) was added directly to the column and
incubated at room temperature for one minute. This was centrifuged at 200 x g for two
minutes, followed by a one-minute spin at 13,000 x g. The eluent was placed back on
column and the step repeated. The concentration of the final product was determined
using the NanoDrop 1000 Spectrophotometer (ThermoScientific, Waltham, MA). The
RNA product was stored at -80℃ until needed.
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Following extraction, 300ng of mRNA product was treated with 0.5-1U DNaseI
(Invitrogen, Carlsbad, CA) for 15 minutes at room temperature and 1µl 25mM EDTA
was added. The DNaseI was heat inactivated at 65°C for 10 minutes. This product was
transcribed to cDNA using Applied Biosystems High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA) and a sample with reverse
transcriptase enzyme (+RT) as well as a control sample without enzyme (–RT), were
created for each sample according to the manufacturer’s protocol. Once the reactions
were loaded in the appropriate tubes, the reaction was run in a thermocycler with the
following parameters: 25℃ for 10 minutes, 37℃ for 2 hours, 85℃ for 5 minutes and
held at 4℃ until collection. These samples were stored at -20℃ for future use.
The PCR cocktail was prepared for a final volume of 20μl containing SYBR
Advantage qPCR Master Mix at a final concentration of 1X, a ROX-LSR reference dye
(Clonetech, Mountain View, CA) and 0.2μM of the appropriate primers (Table 2). Oct4A
and Oct4 variant expression were assessed with a probe-based assay (IDT). Cocktails
were made according to manufacturer’s protocol. Following this, samples were treated
the same as the other primer sets. Template or water was added to the cocktail in its
respective tube. cDNA samples were run in triplicate and three no template controls
(NTCs) created for each gene. A control cDNA sample was serially diluted to create
standard curves for each gene and the efficiency of each primer set was determined. The
PCR reaction was set up using the software for the Applied Biosystems 7300 qPCR
Machine. The reaction was carried out as follows: initial denaturation for 2 minutes at
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95℃, denaturation at 95℃ for 40 cycles at 5 seconds each, annealing at 60℃ for 40
cycles at 30 seconds each, extension at 70℃ for 40 cycles at 30 seconds each and
dissociation at 95℃ for 15 seconds, 60℃ for 1 minute, 95℃ for 15 seconds and 60℃ for
15 seconds. The annealing temperature varied depending on the primer set (
Appendix B). The results were analyzed with Applied PCR 7300 Analysis
software.
To analyze the PCR product, a 2-3% agarose gel was prepared and run with 1X
TAE Buffer. Loading dye was added to each PCR product to give a final concentration
of 1X. Half of this volume was loaded into subsequent wells and run at 70 volts for one
to two hours, stained in ethidium bromide and rinsed in dH2O. Stain and rinse incubation
times varied depending on the amount of agarose. The gel was imaged using the
AlphaImagerHP MultiImage II (Alpha Innotech).
Data Analysis

Gene expression data for each gene was normalized to Gapdh expression and
relative expression determined using a modified Michael W. Pfaffl equation which
accounts for varied primer efficiencies (Pfaffl 2004). These data are given as Mean ±
Standard Error (SE). Additionally, dissociation curves were produced for each sample to
account for the decreased specificity of SYBR. This was not performed for the probebased assays. The significance of these data was determined by performing a one-way
ANOVA in R Studio for each gene. Tukey’s HSD analysis was performed on ANOVA
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results which produced p-values less than 0.05. All ICC images were processed
identically to ensure they were comparable and co-localization was assessed using the
ZEN imaging software from Carl Zeiss (Zeiss).

25
RESULTS

Characterizing cJun Over Expression in mESCs Transiently Transfected with PLVXGFPcJun and PLVX-GFP L40/42A

If cJun regulates Oct4 variant expression, one would expect ectopic
overexpression of the cJun protein would affect Oct4 mRNA levels. Furthermore, if cJun
regulates transcription of the Oct4 mRNA directly, cells in which the transcriptionally
inactive cJun mutant L40/42A is expressed should have a different effect on Oct4 mRNA
levels when compared to control cells than those overexpressiong wild type cJun. To test
these hypotheses, pLVXGFP, pLVX GFP cJun and the pLVX GFP cJun L40/42A mutant
plasmids were transfected into mES cells with Lipofectamine 3000, plated onto gelatin
and harvested 36 hours post transfection, after transfection efficiency was confirmed by
flourescent microscopy of GFP. mRNA was isolated and converted to cDNA. To identify
for biological variation, the transfections were performed in triplicate 3-4 times.
As immunoblot data from our lab demonstrates that endogenous cJun is
expressed in J1 mES cells cultured on irradiated MEFs in LIF media (Figure 3 and not
shown) and transfection efficiency was relatively low (< 20%), we developed two qPCR
primer sets for cJun mRNA quantitation. One was directed to transcripts produced by the
cJun loci in the genomic DNA as well as those from the pLVXcJun and L4042 plasmids
(cJun primers). The second set was designed such that the forward primer was
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complimentary to pLVX sequences 5’ of the cJun coding sequence in the plasmid
(pLVXcJun primers).
When cJun cDNA was quantified using the cJun primers and compared to cJun
transcript levels in untransfected control cells, the expression levels normalized to NT
showed a 41.45±8.44 fold increase in cells transfected with the pLVX cJun plasmid and a
32.81±14.54 fold increase in those transfected with pLVXL4042. These were
significantly higher than expression levels seen in cells transfected with pLVXGFP,
which had a fold change of 1.13±0.34. When the pLVX cJun primers were used to
quantify cJun cDNA levels, the fold change expression of pLVX cJun transcripts
compared to untransfected controls was 650.93±314.5 for cJun, 154.3±61.53 for
L40/42A and 4.92±3.22 and for GFP. Unlike the products produced by the cJun primers,
only one band of the appropriate size was generated in these reactions. (Figure 4 and
Table 2 )
The slightly increased expression of cJun in the cells expressing GFP alone
suggested the plasmid transfection appeared to have an effect on gene expression in
general. Knowing the GFP plasmid did not contain endogenous cJun, we evaluated the
levels of cJun normalized to GFP expression. The GFP normalized cJun expression data
generated with the cJun primers were 38.96±16.16 and 31.97±13.18 for cells transfected
with cJun plasmid and L40/42 respectively. The GFP normalized cJun expression data
generated with the pLVXcJun primers was 199.28±52.73 and 61.87±29.9 for cJun and
L40/42 transfected cells, respectively. A one-way ANOVA was performed on these data
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and found that cJun expression normalized to NT alone varried significantly (p<0.05,
n=3, F(3,8)= 6.306). Tukey’s HSD determined that cJun expression varied significantly
between cJun transfected cells and NT or GFP samples (p<0.05, n=3,). One way
ANOVA did not show any statistically significant difference between treatments with
cJun data normalized to GFP. Plasmid expression normalized to both NT and GFP were
significant by one-way ANOVA, p<0.05 and p<0.01 for NT(F(3,12)= 3.673) and GFP
normalized (F(2,9)= 9.747), respectively (n=4).Tukey’s HSD showed that plasmid
expression normalized to NT was not as significant with p<0.1(n=4) for cJun transfected
cells compared to NT or GFP samples. Plasmid expression normalized to GFP were
significant for cJun samples compared to NT (p<0.05) and GFP (p<0.01) by Tukeys HSD
test (n=4). Gel analyses of these samples showed that cJun and L40/42 transfected
samples produced multiple bands, however dissociation curve analysis did not always
produce multiple peaks for cJun primers (Figure 4 and Table 2). Although the pLVXcJun
primers produced multiple dissociation peaks, gel analysis demonstrated only one
prominent band at the predicted size of 70bp (Figure 4). Because of this, we utilized
pLVX expression as an analog for transfection efficiency and thus a marker for cJun over
expression.
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Figure 4. cJun primers produced multiple bands upon agarose gel analysis while
pLVX primers produced singular bands. A. A representative image of both cJun
and pLVXcJun PCR products. Dissociation curve analysis of cJun primers produced
multiple peaks and multiple bands on the gel (lanes 4-6). One sample did produce a
dissociation curve with one clear peak, but still showed multiple bands on the gel
(lanes 1-3). This could be due to amplification of the transfected plasmid resulting in
single strands. The pLVXcJun primers always produced one band at 70bp, but almost
all replicates had dissociation curves with 2 peaks (lanes 10-12 and 13-15). Two
replicates had one dissociation peak, but only one was analyzed on a gel and also
produced one band at 70bp (lanes 7-9). The second dissociation peaks were small and
could be due to GC or AT rich regions in the sequence that would cause a small
secondary peak once it dissociated. B. An example of the multiple bands seen with
cJun primers. Here more distinct bands can be seen and each sample had dissociation
curves with multiple peaks. Lanes are labeled with replicate date, then sample as
follows: 1-3) 32 L40/42, 4) 32 cJun, 5) 510L40/42, and 6) 530 L40/42. These data are
also summarized in table 2.
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Table 2. List of cJun and pLVXcJun samples, Ct value, approximate dissociation
temperatures, number of each triplicate affected and number of bands present on
agarose gel. Only samples transfected with the L40/42 cJun mutant or GFP cJun
produced variable data. Upon gel analysis, all cJun samples showed multiple bands for all
triplicates, however dissociation curve analysis did not always show multiple peaks for
those triplicates. Ct values were all within 1 Ct value, demonstrating that expression was
not greatly affected by the additional bands. In contrast to cJun expression, amplification
with plasmid primers produced dissociation curves with multiple peaks, but only one
band upon gel analysis. The multiple dissociation peaks were inconsistent and did not
affect all triplicates. Asterisk indicates samples not used in data analysis.

Replicate

Treatment

Primer
set

Average
Ct value

Approximate
dissociation
temperature
(ºC)

# of
triplicate

Bands
present

1

GFP

cJun

14.29

85

3

No gel run

1

L40/4
2

cJun

18.08

87

3

No gel run

1

cJun
(plasm
id)

cJun

16.61

87

3

No gel run

2
2

GFP
L40/4
2

cJun
cJun

23.12
17.67

85
84 and 87

3
3

No gel run
118bp,
290bp, 500bp

2

cJun
(plasm
id)

cJun

18.45

84 and 87

1

118bp,
190bp, 290bp

3
3

GFP
L40/4
2

cJun
cJun

20.85
21.77

85
84 and 87

3
1

No gel run
118bp,
multiple
bands of
indeterminant
size in the
190-700bp
range

Fold
change
expression
normalized to
NT or
GFP
NT:
262.99*
NT:
8.65*,
GFP:0.0
3*
NT:
30.57*,
GFP:0.1
3*
NT: 0.57
NT:
29.96,
GFP:
53.01
NT:
48.79,
GFP:
86.35
NT: 1.1
NT: 9.17
GFP:8.3
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Replicate

Treatment

Primer
set

Average
Ct value

Approximate
dissociation
temperature
(ºC)

# of
triplicate

Bands
present

3

cJun
(plasm
id)

cJun

16.88

85 and 87

3

4
4

GFP
L40/4
2

cJun
cJun

20.95
16.69

85
84 and 87

3
1

4

cJun
(plasm
id)

cJun

17.28

85

3

1

GFP

40

78, 84

3

1

L40/4
2

pLVXc
Jun
pLVXc
Jun

Multiple
bands of
indeterminant
size between
118-190bp
No gel run
118bp, bands
of
indeterminant
size ≥ 500bp
bands of
indeterminant
size between
118-190bp
and 300500bp
No gel run

34.53

82

3

No gel run

1

cJun
(plasm
id)

pLVXc
Jun

32.47

82

3

No gel run

2

GFP

40

79, 89, 88

3

No gel run

2

L40/4
2

pLVXc
Jun
pLVXc
Jun

33.20

82

3

70bp

2

cJun
(plasm
id)

pLVXc
Jun

32.37

82

3

70bp

3

GFP

38.1

71,76,86

3

No gel run

3

L40/4
2

pLVXc
Jun
pLVXc
Jun

30.61

76 and 82

1

70bp

Fold
change
expression
normalized to
NT or
GFP
NT:24.6
2
GFP:22.
27
NT:1.75
NT:59.3
1
GFP:33.
98
NT:50.9
5
GFP:
29.19

NT: 0.77
NT:
21.81
GFP:28.
98
NT:119.
64
GFP:
168.51
NT: 0.72
NT:
107.84
GFP:149
.2
NT:239.
43
GFP:
331.28
NT:3.89
NT:174.
46
GFP:
44.85
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Replicate

Treatment

Primer
set

Average
Ct value

Approximate
dissociation
temperature
(ºC)

# of
triplicate

Bands
present

3

cJun
(plasm
id)

pLVXc
Jun

30.76

76 and 82, 76
and 90

2

70bp

4

GFP

36.642

70,78

3

No gel run

4

L40/4
2

pLVXc
Jun
pLVXc
Jun

32.68

76 and 82

1

70bp

4

cJun
(plasm
id)

pLVXc
Jun

31.07

76 and 82

2

70bp

Fold
change
expression
normalized to
NT or
GFP
NT:
740.68
GFP:
190.42
NT:14.3
4
NT:313.
41
GFP:
21.86
NT:
1504.03
GFP:
104.89

Overexpresion of cJun Has a Varied Effect on mRNA Expression of Oct4A and
Pluripotency Markers Nanog and Sox2

Having varified transfection of PLVXcJun and PLVXL4042/A leads to over
expression of cJun in each of the four experimental replicates, we were interested in
measuring Oct4 cDNA levels to determine the effect of cJun overexpression on this
important pluripotency marker. As the level of Oct4 protein affects cellular potency, we
also determined gene expression for two other pluripotency factors, Nanog and Sox2.
Primer sets were validated by amplifying both cDNA from mESCs and DNA, correct
amplicon size confirmed, and sequenced for correct amplicon sequence. The gels for this
can be seen in Figure 5 and produced the following amplicon sizes: 230bp (Gapdh),
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118bp (cJun), 70bp (GFPcJun plasmid), 364bp (Nanog), 207bp (Sox2), and 111bp
(Oct4A).
When normalized to untransfected cells (NT), Oct4A cDNA was 1.52±0.3 fold
higher in pLVX cJun transfected cells , 1.62±0.86 fold higher in PLVX L40/42
transfected cells and 1.36±0.4 fold higher in cells transfected with PLVX GFP. When
normalized to Oct4A levels in cells expressing GFP, fold expression was 1.29±0.31 and
1.5±0.9 higher for cells expressing with cJun and L40/42 respectively. Nanog gene
expression was 1.54±0.7, 1.22±0.43, and 1.17±0.42 for cJun, L40/42, and GFP
transfected cells respectively. GFP normalized data were 1.15±0.28 and 1.02±0.17 for
cJun and L40/42 respectively. Similarly, Sox2 gene expression was 2.20±1.27, 3.61±2.75,
and 1.45±0.67 for cJun, L40/42, and GFP transfected cells respectively. GFP normalized
data were 1.31±0.32 and 1.72±0.62 for cJun and L40/42 respectively (Figure 5). Oneway ANOVA analyses of NT and GFP normalized data produced no statistically
significant difference between treatment for any gene (p>0.05, n=4). The affect of cJun
over expression is variable and may be due to variations in transfection efficiency in each
replicate. While not statistically signifcant, as changes in Oct4 expression of 1.5 fold
have been demonstrated by others to have biological affects (Niwa 2000), the increases
seen in the presence of cJun and L4042 are expected to effect potency. Therefore, it is
possible the mild increases in Nanog and Sox2 expression could also have biological
implications.
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A.

B.
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Figure 5. Overexpression of cJun affects expression levels of Sox2, and Oct4A. A.
A graph of NT normalized expression data for Oct4A, Nanog and Sox2. B. Graph of
the same expression data normalized to GFP. C. Table showing gene expression of
cJun and plasmid (pLVXcJun primers) to demonstrate cJun over expression and
plasmid transfection efficiency. Because transfection efficiency varied between
replicate and between treatments, plasmid expression will be used as a marker for
overexpression, in place of cJun expression. D-I. Gels of PCR amplified cDNA to
confirm the correct amplicon size for each gene: Gapdh (D), Sox2 (E), Nanog (F),
GFPcJun plasmid (G), cJun (H), and Oct4A using primers for SYBR analysis (I).
Because the Oct4 gene produces multiple mRNA variants, we used a previously
validated probe-based assay (Integrated DNA Technologies, Skokie, Illinois) to see if
transfection with cJun affected variant expression. Oct4A gene expression was measured
with a primer and probe set designed to bind exon 1, which is only present in the Oct4A
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mRNA variant. These primers did not amplify genomic DNA under the experimental
conditions, despite the presence of the forward and probe sequences in exon1 and the
reverse in exon 2. The intron 1 sequence is a little over 2,300bp, which cannot be
amplified in the 30sec annealing and elongation steps. The primer probe combination
used to analyze exon 2 recognizes five Oct4B variants, Oct4b’, Oct4b, Oct4b1, Oct4b2,
and Oct4b3:. These primers did not initially amplify cDNA from mESCs, but did
amplify from genomic DNA as well as cDNA generated from embryoid bodies (EBs).
Finally, we used a primer and probe set which amplified exon 5, which is conserved over
all Oct4 mRNA variants. The exon 5 primers were designed to not amplify genomic
DNA with a probe that spans an intron sequence, ensuring an trace amounts of genomic
contamination would not be quantified (Figure 7). These data were normalized to
untransfected (NT) and then to GFP in the same manner as the previous genes. When
normalized to NT expression levels, Exon 1 expression was 1.73 ±0.36 fold higher for
cJun transfected cells, 0.96±0.35 for the L40/42 and 1.58±0.63 for GFP transfected cells.
The fold change for GFP normalized data was 1.35±0.19 and 0.94±0.47 for cJun and
L40/42 respectively. Exon 2 expression was 2.71±1.1, 16.91±16.5, and 1.23 ±0.72 for
cJun, L40/42, and GFP transfected cells. Expression for GFP normalized data were
5.97±4.73 and 74.21±73.51 for cJun and L40/42, respectively. Exon 5 gene expression
was 1.51±0.25 for cJun transfected cells and 1.33±0.58 and 0.69±0.28 for the L40/42 and
GFP controls. GFP normalized data were 4.13±2.2 and 6.5±5.2 for cJun and L40/42,
respectively.
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Dispite the large differences in Oct4 expression levels seen in the presence of
cJun and L40/42, a one-way ANOVA of these data, both NT and GFP normalized, did
not show any significant difference in fold change between treatment for any gene
(p>0.05, n=4) (Figure 6), likely due to the large standard error among the averaged
samples. To see if the difference in Ct values were the result of irregular qPCR
amplification among the replicates, these samples were run on agarose gels to confirm
the expected base pair sizes of 111bp, 91bp, and 135bp for exon 1, exon 2, and exon 5
respectively (Figure 5 A-C). We found that exon 2 and exon 5 produced additional bands
and smears, while exon 1 produced this result to a lesser extent. Upon analysis of new
transcript sequences the new expected base pair band became 91bp (Oct4b’), 296bp
(Oct4b2 and Oct4b3), and 297bp (Oct4b and Oct4b1) for exon 2. New expected sizes for
exon 5 were 135bp for Oct4A, Oct4b’, Oct4b, and Oct4b1 and 274bp for Oct4b2 and
Oct4b3. Additional bands seen by agarose gel were between 100-900bp for exon 2, with
the brightest bands at 296bp, indicating amplification of either Oct4b2, Oct4b3, Oct4b, or
Oct4b1. Bands for exon 5 were between 135-800bp, with bright bands at the expected
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135bp, indicating less expression of Oct4b2 and Oct4b3. Exon 1 produced only one band
on the gel at the expected 111bp size (Figure 7 and
Figure 7. Exon 1 primers produce one amplicon, while exons 2 and 5 produce
multiple bands from various Oct4B variants. A. Agarose gel of exon 1. Only one band
is seen at the expected 111bp. There do appear to be very faint bands below these, which
are assumed to be primer dimers or other noise, as they also appear in the –RT samples.
Lanes 1-24 are triplicates for each treatment of one replicate and are consistent between
treatments. Lanes 4-6 are NT, GFP are lanes 10-12, L40/42 are lanes 16-18, and cJun
transfected samples are lanes 21-24. The remaining lanes are the corresponding –RT
samples. B. Agarose gel of Exon 5. NT samples are in lanes 4-6., GFP in 10-12, L40/42
in 16-18, and cJun samples in lanes 21-24. You can see multiple bands in all samples. C.
Agarose gel of exon 2. Lanes 4-6 are NT samples, 10-12 are GFP, 16-18 are L40/42, and
21-24 are cJun samples. Multiple bands can be seen in GFP, L40/42 and cJun samples.
The bands in the L40/42 and cJun treatments are more abundant and varied in size.
Additionally, cJun and L40/42 samples contain the largest band at about 1000bp and
900bp, respectively. These upper bands, denoted by the two white arrows, are faint but
distinct. D. Agarose gel analysis of all the Oct4 primers off cDNA (lane2) and genomic
DNA (lane 3). Exon 1 did not amplify in the no template control (NTC) sample (lane 1)
or the genomic DNA. Similarly, exon 5 did not amplify the NTC (lane 7) or genomic
DNA (lane 9), but did amplify cDNA (lane 8). Exon 2 only amplified the genomic DNA
(lane 6). Because of this EB cDNA was used. E. Agarose gel analysis of exon 2 primers
amplifying cDNA from embryoid bodies (EBs). Lane 1 shows the primers amplify
genomic DNA and lane 3 shows they will amplify cDNA from EBs. Lane 2 shows the
primers will not amplify the –RT sample.
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Table 3). Because exon1 primers only produced one band and the probe sequence
removes background qPCR signal, we assumed the extra bands seen on the gel for exon 2
and exon 5 only affect the calculated expression data if the bands contain the probe
sequence and are variations on the known Oct4B variants.
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A.

B.
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C.

D.
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E.

F.
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Figure 6. cJun over expression increases gene expression of Oct4B variants. A. NT
normalized graph of exons 1, 2, and 5. Exon 2 data were much larger than exon 1 or 5 so
it was removed and graphed separately (C. and F.). B. NT normalized data of exons 1
and 5. C. NT normalized data for exon 2. D. GFP normalized data for all exons. E. GFP
normalized data for exons 1 and 5. F. GFP normalized data for exon 2. G. Table of
plasmid expression from figure 5, for reference.
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Figure 7. Exon 1 primers produce one amplicon, while exons 2 and 5 produce
multiple bands from various Oct4B variants. A. Agarose gel of exon 1. Only one band
is seen at the expected 111bp. There do appear to be very faint bands below these, which
are assumed to be primer dimers or other noise, as they also appear in the –RT samples.
Lanes 1-24 are triplicates for each treatment of one replicate and are consistent between
treatments. Lanes 4-6 are NT, GFP are lanes 10-12, L40/42 are lanes 16-18, and cJun
transfected samples are lanes 21-24. The remaining lanes are the corresponding –RT
samples. B. Agarose gel of Exon 5. NT samples are in lanes 4-6., GFP in 10-12, L40/42
in 16-18, and cJun samples in lanes 21-24. You can see multiple bands in all samples. C.
Agarose gel of exon 2. Lanes 4-6 are NT samples, 10-12 are GFP, 16-18 are L40/42, and
21-24 are cJun samples. Multiple bands can be seen in GFP, L40/42 and cJun samples.
The bands in the L40/42 and cJun treatments are more abundant and varied in size.
Additionally, cJun and L40/42 samples contain the largest band at about 1000bp and
900bp, respectively. These upper bands, denoted by the two white arrows, are faint but
distinct. D. Agarose gel analysis of all the Oct4 primers off cDNA (lane2) and genomic
DNA (lane 3). Exon 1 did not amplify in the no template control (NTC) sample (lane 1)
or the genomic DNA. Similarly, exon 5 did not amplify the NTC (lane 7) or genomic
DNA (lane 9), but did amplify cDNA (lane 8). Exon 2 only amplified the genomic DNA
(lane 6). Because of this EB cDNA was used. E. Agarose gel analysis of exon 2 primers
amplifying cDNA from embryoid bodies (EBs). Lane 1 shows the primers amplify
genomic DNA and lane 3 shows they will amplify cDNA from EBs. Lane 2 shows the
primers will not amplify the –RT sample.
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Table 3. Summary of bands present on agarose gel for exon 1, exon 2, and exon 5
and the corresponding treatment condition they were located. A comparison of
expected amplicon sizes with the amplicons seen on agarose gel. While many bands were
expected for the Oct4B variants, there were additional bands that were not expected.
These may be additional sequences as of yet unidentified. They may or may not have
contributed to the expression data, as dissociation curves cannot be run on probe assays.

Primer set

Expected bands

Bands present

Treatment

Exon 1

1 band-111bp

1 band- 111bp

All

Exon 2

Oct4b’: 91bp

296 or 297bp

All

Oct4b2 and 3: 296bp

350bp

cJun and L40/42

Oct4b and b1: 297bp

900bp

L40/42

1000bp

cJun

multiple indistinct bands
of indeterminate size in
the range of 100-296bp.

GFP, L40/42, and
cJun

135bp

All

Exon 5

Oct4A, Oct4b’, Oct4b
and Oct4b1: 135bp
Oct4b2 and 3: 274bp

300bp
350bp
400bp

cJun and L40/42

500bp

cJun and L40/42

cJun Over Expression Increases Gene Expression of Endoderm Markers

As the changes Oct4 variant expression and the increased Sox2 cDNA levels
presents in cJun and L40/42 overexpressing cells are expected to affect potency, we
measured transcript levles of germ layer markers Brachyury, Sox1, Gata4, and Gata6 to
determine whether a shift in gene expression of pluripotency factors would initiate
expression of these germ layer markers and if there was a bias towards one germ layer or
another. Expression of the mesoderm marker Brachyury was 1.02±0.38, 0.83±0.06, and
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1.24±0.35 fold higher for cJun, L40/42, and GFP transfected cells. GFP normalized data
were 1.04±0.42 and 0.88±0.27 for cJun and L40/42 samples. The ectoderm marker, Sox1,
showed 1.14±0.48, 1.49±0.44, and 1.05±0.37 fold changes in expression for cJun,
L40/42, and GFP, respectively. Expression for cJun and L40/42 samples normalized to
GFP were 1.01±0.4 and 3.66±2.76, respectivley. Gata4 expression, a marker for
endoderm, was 1.39±0.37, 1.39±0.61, and 0.97±0.12 for cJun, L40/42, and GFP samples.
GFP normalized data were 1.41±0.34 and 1.43±0.61 for cJun and L40/42, respectively.
Primative endoderm marker, Gata6, produced a fold change of 2.54±0.69 in cJun
transfected cells and 2.3±1.12 and 1.52±0.31 for L40/42 and GFP transfected samples,
respectively. These data normalized to GFP were 1.63±0.39 and 1.46±0.53 for cJun and
L40/42 (Figure 8). One-way ANOVA analyses of NT and GFP normalized data did not
produce statistical significance between treatment for any gene (p>0.05, n=4). While
samples were not analyzed by gel electrophoresis, they were validated in the same
manner as previously mentioned and produced the expected amplicon sizes: 134bp
(Sox1), 117bp (Brachyury), 225bp (Gata4), and 182bp (Gata6) (Figure 8).
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A.

B.
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Figure 8. Figure 8. Over expression of cJun increases expression of Gata6
and Gata4. A. NT normalized expression data. B. GFP normalized expression
data. C. Table of plasmid expression for reference. D. Agarose gel of Sox1,
which produced the expected 134bp band. E. Agarose gel of Brachyury, which
produced the correct 117bp amplicon. F. Agarose gel of Gata4 (lane 1) and Gata6
(lane 2), which produced 225bp and 182bp bands respectively.

Nocodazole Increases cJun Gene Expression and Effects Oct4 Variant Gene Expression
in mESCs

Nocodazole treatment of cells was shown to increase in cJun protein expression
through an alternative translation pathway without a proportional increase in mRNA
expression (Polak et al. 2006, Blau et al. 2012, unpublished data Sprowles Lab).
Furthermore, the cJun proteins produced through this mechanisms have different
transcriptional targets than those generated from increased transcription (Blau et al.
2012). We used SYBR qPCR assays to quantify cDNA levels of cJun, Oct4A, Nanog,
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Sox2. Overall, cJun expression was increased with nocodazole treatment (Table 4).
However, the range of cJun cDNA between replicates was highly variable, so a one-way
ANOVA performed on these data and was not statistically significant (p> 0.05, n=3). The
large variation in expression data (data not shown) could be due to the small replicate
number of 3, but because DMSO also exhibits a varied effect on expression, the variation
may be due to a dosage effect from both DMSO and nocodazole. Nonetheless, there are
trends observed when relative levels of cJun are taken into account.There is a general
decrease in Nanog expression with decreasing cJun for both nocodazole and DMSO
treatment. Expression of Sox2 does not seem to have any relation to cJun expression due
to nocodazole or DMSO. Expression of Oct4 using SYBR varies wildy with nocodazole
treatment, while the same primers in the probe assay does not (Table 4). Interestingly,
Oct4A expression does not vary greatly in DMSO samples, despite one replicate
containing multiple dissociation peaks and 2 bands upon gel analysis (Figure 9). The
additional band between 1200bp and 1500bp could be a product of a currently unknown
mechanism as a reaction to DMSO and may be dose dependent as no other replicate
treated with DMSO produced the same effect. The expression pattern for Nanog, Sox2,
and Oct4A was similar with DMSO normalized data, however the variance is slightly
decreased.
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Table 4. Increases in cJun expression associate with increases in Oct4 variants and
decreases in Nanog expression. A. NT normalized data for each gene assayed by both
SYBR and probe-based assays. B. DMSO normalized data for each gene evaluated by
STBR and probe-based assays. For both tables, expression values associated with
nocodazole treated samples are in aqua, while the values associated with DMSO
treatment are in peach.

A.
Replicate

Treatment

cJun

Oct4A SYBR

Nanog

Sox2

Oct4A
exon 1

Oct4B
exon 2

Oct4all
exon 5

1

NT

1

1

1

1

1

1

1

1

DMSO

0.29

3.45

0.74

3.94

2.00

2.41

1.82

1

Nocodazole

2

NT

50.67

538.76

0.35

3.53

3.24

3.08

30.03

1

1

1

1

1

1

1

2

DMSO

1.20

2.88

0.91

1.20

1.41

2.38

7.55

2

Nocodazole

51.84

4.72

0.36

0.75

3.72

0.39

2.85

3

NT

1

1

1

1

1

1

1

3

DMSO

0.69

6.98

2.89

0.57

0.19

1.08

0.23

3

Nocodazole

1.84

1335.16

1.89

0.46

0.24

1.07

0.30

Replicate

Treatment

cJun

1

DMSO

1

Nocodazole

2

DMSO

2

Nocodazole

3

DMSO

3

Nocodazole

B.
Oct4A SYBR

Nanog

Sox2

Oct4A
exon 1

Oct4B
exon 2

Oct4all
exon 5

1

1

1

1

1

1

1

169.89

155.79

0.47

0.89

1.62

1.27

16.48

1

1

1

1

1

1

1

43.10

1.63

0.40

0.62

2.63

0.16

0.37

1

1

1

1

1

1

1

2.65

191.17

0.65

0.80

1.23

0.99

1.31
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Figure 9. DMSO produces multiple bands in one replicate amplified by Oct4A
primers. Exon 1 primers used in sybr assays produced multiple dissociation peaks (data
not shown) and produced multiple bands on a gel. The expected 111bp band is clearly
seen in all samples, but there is a large and bright band between 1200-1500bp. This does
not appear to affect the expression data for this replicate, as it is similar to another
replicate with similar cJun expression. Lanes 1-3 are NT, 4-5 DMSO, and lane 7 is one
triplicate of the nocodazole sample for the same replicate. Both NT and nocodazole
samples produced one clear dissociation peak.

Similar to transfection data, we assessed the expression of the Oct4 mRNA
variants using a probe-based assay. Generally, when there was an increase in cJun
expression from either DMSO or nocodazole, there was an increase in Oct4 expression.
DMSO appears to affect Oct4B variants, while nocodazole appears to have an increased
effect on Oct4A versuses the other variants. These tentative relationships appear to be
dose dependant, as intermediate cJun levels produce an intermediate effect on Oct4
expression (Table 4). Additionally, when Oct4A increases the Oct4B variants decrease.
These trends are weak, but are potentially affected by the low sample size and the
multiple bands seen by agarose gel electrophoresis. Like the transfected samples,
mulitple bands were seen for the Oct4 variants. Exon 1 primers produced the expected
111bp band and 2 additional bands at 200bp and 400bp. The additional bands are only
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seen in DMSO and nocodazole samples for all replicates and indicate an unaticipated
effect of both DMSO and nocodazole on Oct4A expression. Exon 5 produced multiple
bands in all treatments, however NT only contains the expected 135bp and 274bp bands.
Additional bands seen in DMSO and nocodazole treated samples were approximately
350bp and 450bp. This could be due to differences in splicing as yet to be defined.
Similar to exon 1, exon 2 produced multiple unexpected bands in DMSO and nocodazole
samples. NT samples produced one clear band at approximately 296-297bp, which
corresponds to the Oct4b and Oct4b1-3 variants. The expected 91bp band for Oct4b’ may
be the faint bands below, but could also be primer dimers as this band is also seen
occasionally in the –RT and NTC samples, which showed no amplification on qPCR
analysis. DMSO samples produced the 296-297bp band as well, but also produced a
550bp band and multiple bands between 250-90bp. Nocodazole produced the expected
band as well as more clear bands at 250bp and 90bp (Figure 10).These variations in band
sizes could explain the variation in expression data as band intensities and number of
additional bands varied slightly between each replicate.
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Figure 10. DMSO and nocodazole treatment have an effect on Oct4 variant
expression. A. A representative agarose gel of exon 1. DMSO and nocodazole treatment
have a clear effect on Oct4A expression, producing bands that were not expected at
about 300bp and 400bp. Lane 3-6 are NT, Lanes 10-12 and 16-18 are DMSO and
nocodazole samples respectively. Remaining lanes are corresponding –RT samples
which did not amplify on qPCR analysis. B. A representative gel of exon 5. Multiple
bands are seen in all samples, however additional bands that were unexpected were seen
only in DMSO and nocodazole samples. Two bands are expected for exon 5 primers at
135bp and 274, which cover all known Oct4 variants. These are seen in all samples, but
additional bands at 350bp and 450bp are seen in DMSO and nocodazole treated samples.
Lanes 4-6 are NT, lanes 10-12 are DMSO and lanes 16-18 are nocodazole samples.
Remaining lanes are corresponding –RT samples. C. Representative gel of exon 2. Like
exon 1, only one band is seen in the NT sample approximately 297bp, indicating any of
the four Oct4B variants, Oct4b and Oct4b1-3. Oct4b’ at 91bp may or may not be the
faint lower bands seen. DMSO and nocodazole samples have clear bands at approximate
297bp, but also have additional bands. Nocodazole produces multiple bands around
250bp and 90bp, while DMSO produces these and others of indeterminate size in that
range of 250-90bp. DMSO produces an additional clear band at approximately 550bp.
Lanes 4-6 are NT, lanes 10-12 are DMSO, and lanes 16-18 are nocodazole samples.
Remaining lanes are corresponding –RT samples.

Because Oct4A is essential in maintaining potency of stem cells and because
variations in protein expression can direct cell fate, indentifying whether or not the
changes in gene expression are seen as changes in protein expression in the same cell will
further support the hypothesis that cJun directly regulates the expression of Oct4A. The
use of ICC allowed for localization of the either cJun and Oct4A or cJun and Oct4all (all
Oct4 protein variants) to the individual cell level. If the signals were co-localized, this
would indicate that cJun is regulating expression of Oct4 variants and suggests that
increases in cJun correlate to increases in Oct4 within the same cell, which may lead to
changes in potency and cell fate. ICC analysis of these data showed variation in cJun,
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Oct4A/B and Oct4all protein expression between and within replicates. Despite this,
there are some trends that suggest cJun and Oct4 expression are affected by nocodozole.
Generally, nocodazole appears to increase cJun and Oct4A/B expression, with
overlap within the bright spots (Error! Reference source not found.). Like the qPCR
data, there is an increase in DMSO treatment, but nocodazole increases the trend, with
the largest cellular co-localization of cJun and Oct4 A/B/B’ occuring 4h post-nocodazole
treatment. Where bright Oct4A/B/B’ points are seen, there are corresponding spots of
cJun signal, however the Oct4A/B/B’ spots do appear to be smaller (Error! Reference
source not found.). Analysis of these spots using the Zeiss co-localization software
seemed to support these findings. The replicate data were pooled (n=3) and analysed as a
number of spots out of the total identified. There were approximately 1-3 cell colonies
per image and increases in co-localized spots did not appear to increase with colony
number. For cJun and Oct4A images, there were an average of 2.05 ± 0.29 colonies for
NT, 1.94 ± 0.47 for 2h DMSO treatments, 2.1 ± 0.23 colonies for 4h DMSO, and 2.04 ±
0.23 colonies and 1.67 ± 0.17 colonies for 2h and 4h nocodazole treatments, respectively.
When cJun protein expression was compared to that of all Oct4 protein isoforms within
the cells, there are few spots identified per colony of cells imaged, but the ratio of
identified co-localization to total number of colonies evaluated for each treatment
gradually increases with nocodazole treatment. The greatest difference in this ratio is
seen between NT and 4h nocodazole treated samples, however the increase is not as large
when looking at co-localizations that had both a strong Pearson’s coefficient (≥0.1) and a
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strong Mander’s coefficient (≥0.98) or higher, as defined by Zinchuk et. al (2007).
Aproximately 48% of all co-localized spots had at least a strong Pearson’s and a strong
Mander’s in NT samples, but only 51% were seen with samples 4h post nocodazole
treatment. Interestingly, 2h post nocodazole treatment had 81% of co-localized spots with
these criteria (Table 5). This indicates that nocodazole treatment increases cJun colocalization with Oct4A, but a stronger degree of co-localization is seen in 2h nocodazole
samples compared to the 4h samples.
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A.
DAPI

cJun

Oct4A/B

cJun +
Oct4A/B

NT
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B.
DAPI

cJun

Oct4A/B

cJun +
Oct4A/B

2h DMSO
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C.
DAPI

cJun

Oct4A/B

cJun +
Oct4A/B

4h DMSO
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D.
DAPI

cJun

Oct4A/B

cJun +
Oct4A/B

2h Nocodazole (5ug/ml)
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E.
DAPI

cJun

Oct4A/B

cJun +
Oct4A/B

4h Nocodazole (5ug/ml)
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F.
DAPI

cJun

Oct4All

cJun +
Oct4All

NT
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G.
DAPI

cJun

Oct4All

cJun +
Oct4All

2h DMSO
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H.
DAPI

cJun

Oct4All

cJun +
Oct4All

4h DMSO
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I.
DAPI

cJun

Oct4All

cJun +
Oct4All

2h Nocodazole (5ug/ml)
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J.
DAPI

cJun

Oct4All

cJun +
Oct4All

4h Nocodazole (5ug/ml)

67
Figure 11. Nocodazole treatment increases co-localization of Oct4A/B or Oct4all
with cJun. A-E. Comparison of cJun expression with Oct4A/B expression across all
treatments to determine the effect of nocodazole on cJun expression as well as the colocalization of cJun to Oct4A. Generally, there is a decrease in cJun with nocodazole and
an increase in Oct4A/B expression, with bright areas generally becoming very small and
widely dispersed. A. NT. B. 2h DMSO. C. 4h DMSO. D. 2h nocodazole. E. 4h
nocodazole. F-J. Comparison of cJun expression with all Oct4 variants (Oct4all).
Nocodazole appears to increase cJun and Oct4all, but the localization changes. Similarly,
to Oct4A/B, bright spots of Oct4all signal do seem to correlate to cJun. F. NT. G. 2h
DMSO. H. 4h DMSO. I. 2h nocodazole. J. 4h nocodazole. Arrows in both images
indicate a few, but not all, of the areas where co-localization was identified.
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D.
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DAPI
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F.
DAPI

cJun

Oct4All
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Figure 12. Nocodazole has varied affect on cJun and Oct4 protein expression. A-E.
An example of variation seen between replicates for Oct4A/B. These data exhibit a more
stark decrease in Oct4A/B and a larger increase in cJun expression. Bright spots of
Oct4A signal still co-localize with cJun. A. NT. B. 2h DMSO. C. 4h DMSO. D. 2h
nocodazole. E. 4h nocodazole F-J. An example of the variation seen between replicates
for Oct4all expression. Both cJun and Oct4all expression are dramatically decreased, but
the bright spots still co-localize. F. NT. G. 2h DMSO. H. 4hDMSO. I. 2h nocodazole. J.
4h nocodazole. Arrows in both images indicate a few, but not all, of the areas where colocalization was identified.

Table 5. Nocodazole treatments show increased co-localization of cJun with Oct4A,
but a decrease in co-localization with Oct4all variants. A. Table of Oct4A colocalization with cJun for each treatment condition. Each row contains the number of colocalized spots of the total number of spots identified. Co-localized spots were evaluated
on the Pearson’s and Mander’s coefficients provided by the Zeiss analytical software.
The Mander’s coefficient is the percentage of overlap between the two channels, while
the Pearson’s determines the correlation between pixel intensity of the two channels
(Zinchuk et al. 2007). Very strong Pearson’s values are those greater than 0.85, strong is
0.85 to 0.49, and moderate is 0.49 to 0.1. Weak and very weak Pearson’s coefficients are
0.1 to -0.26 and -0.26 to -1. Very strong Mander’s coefficients are ≥0.98, strong are 0.98
to 0.89, and moderate values are 0.89 to 0.71. Weak and very weak Mander’s coefficients
are 0.71 to 0.5 and 0.5 to 0. These data were then further defined by combinations of the
two coefficients to provide a better co-localization picture. The greatest number of colocalized spots per colony is seen in the 4h nocodazole treatment, but the greatest
percentage of co-localized spots with at least strong Pearson’s and Mander’s coefficients
was seen in the 2h nocodazole sample. B. Table of Oct4all co-localization with cJun.
These data were organized as previously mentioned.

A.
Oct4A co-localization
Very strong Pearson’s
coefficient (≥0.85)
Strong Pearson’s
coefficient (≥0.49)
Moderate Pearson’s
coefficient (≥0.1)

NT

2h
DMSO

4h
DMSO

2h
Nocodazole

4h
Nocodazole

4

3

7

21

3

12

18

9

26

19

12

11

14

5

9
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Oct4A co-localization
Very strong Mander’s
coefficient (≥0.98)
Strong Mander’s
coefficient (≥0.89)
Moderate Mander’s
coefficient (≥0.71)
Very strong Pearson’s
and Very strong
Mander’s
Very strong Pearson’s
and Strong Mander’s
Strong Pearson’s and
Very strong Mander’s
Strong Pearson’s and
Strong Mander’s
Strong Pearson’s and
Moderate Mander’s
Moderate Pearson’s and
Very Strong Mander’s
Moderate Pearson’s and
Strong Mander’s
Moderate Pearson’s and
Moderate Mander’s
Weak Pearson’s and Very
Strong Mander’s
Weak Pearson’s and
Strong Mander’s
Very Weak Pearson’s and
Very Strong Mander’s
Very Weak Pearson’s and
Strong Mander’s
Total number of colocalized spots identified
Total number of cell
colonies for all images

NT

2h
DMSO

4h
DMSO

2h
Nocodazole

4h
Nocodazole

26

40

31

56

22

7

3

11

2

2

0

0

2

0

0

3

3

6

21

3

1

0

1

0

0

10

17

5

24

19

2

1

3

2

0

0

0

1

0

0

8

9

11

5

8

4

2

2

0

1

0

0

1

0

0

4

10

8

2

9

0

0

1

0

0

1

1

1

4

0

0

0

4

0

1

33

43

44

58

41

40

53

54

66

31
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B.
Oct4All co-localization
Very strong Pearson’s
coefficient (≥0.85)
Strong Pearson’s
coefficient (≥0.49)
Moderate Pearson’s
coefficient (≥0.1)
Very strong Mander’s
coefficient (≥0.98)
Strong Mander’s
coefficient (≥0.89)
Moderate Mander’s
coefficient (≥0.71)
Very strong Pearson’s
and Very strong
Mander’s
Very strong Pearson’s
and Strong Mander’s
Strong Pearson’s and
Very strong Mander’s
Strong Pearson’s and
Strong Mander’s
Moderate Pearson’s and
Very Strong Mander’s
Moderate Pearson’s and
Strong Mander’s
Moderate Pearson’s and
Moderate Mander’s
Weak Pearson’s and Very
Strong Mander’s
Weak Pearson’s and
Strong Mander’s
Very Weak Pearson’s and
Very Strong Mander’s
Very Weak Pearson’s and
Strong Mander’s

NT

2h
DMSO

4h
DMSO

2h
Nocodazole

4h
Nocodazole

5

7

1

12

5

7

6

6

9

17

5

5

6

10

23

19

15

12

33
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0

5

8

6

8

0

0

0

0

0

5

7

1

11

5

0

0

0

1

0

7

4

3

6

16

0

2

3

3

1

5

3

4

8

17

0

2

2

2

6

0

0

0

0

0

2

1

4

7

9

0

1

3

0

2

0

0

0

1

2

0

0

0

0

0
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Oct4All co-localization

Total number of colocalized spots identified
Total number of cell
colonies for all images

NT

2h
DMSO

4h
DMSO

2h
Nocodazole

4h
Nocodazole

19

20

20

39

58

36

46

27

41

45

Similarly to Oct4A co-localization, Oct4all co-localization to cJun was assessed.
Generally, there was an increase in cJun and Oct4all with nocodazole treatment and a
localization more towards the cytoplasm. Again, bright spots appear to be co-localized
with cJun in the nucleus, but many bright areas that appear to be cytoplasmic co-localize
with cJun as well (Error! Reference source not found.). In contrast to this, another
replicate showed a dramatic decrease in Oct4all and a slight decrease in cJun. The bright
spots still co-localized with cJun and appeared to be mostly in the nucleus. There was
also a larger increase in cJun and Oct4all for the 4h DMSO samples, which also appeared
to be cytoplasmic (Error! Reference source not found.). Analysis of the co-localized
spots across all replicates (n=3) showed that the number of co-localized spots per colony
increased with nocodazole treatment. Despite this, the degree of co-localization decreased
with nocodazole treatment. Only 38% of identified co-localized spots in 4h nocodazole
samples had at least a strong Pearson’s and Mander’s coffecient, while 54% were seen in
the 2h nocodazole samples and 63% in the NT samples. This would correlate well to the
data seen with Oct4A, as increases in co-localization of Oct4A with cJun would indicate
that these two transcription factors have more of a relationship than cJun with other Oct4
variants.
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DISCUSSION

We aimed to better characterize the effects of cJun on Oct4 expression. To
achieve this, we transiently transfected mES cells with a GFP-cJun construct and a
transcriptionally inactive L40/42 mutant. Addtionally, we utilized a cytoskeleton
disrupting drug, nocodazole, to determine if effects of cJun on Oct4 variants would occur
when endogenous cJun expression was increased under these conditions. Overall, our
data indicates overexpression of cJun by both mechanisms affects Oct4 variant
expression. Previous experiments in our laboratory and the data reported here describing
increased expression of GATA4 and GATA6 in mESCs ectopically expressing GFP-cJun
and GFP-L/40/42A suggest these changes in Oct4 affect the potency of mESCs.

cJun Over Expression Produces an Increase in Oct4 Variants and Affects Other
Pluripotency Markers

Transfection of cJun increased overall levels of cJun cDNA when analyzed by
SYBR qPCR chemistry; however, these data were complicated by multiple bands on gel
analysis and mulitple dissociation peaks. This only occurs in samples transfected with
either cJun or the L40/42 mutant, suggesting ectopic expression of cJun from the pLVX
plasmids are creating additional targets recognized by the primers. As the primers produce
a single band when the purified plasmid is used as template, the most likely cause for
multiple bands is that the mRNA produced from the plasmid is different than that expressed
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from the genomic loci. Some bands on the gel which were too close in size to distinguish
from one another were seen in a few samples which produced only one dissociation peak.
Further experiments will be needed to fully understand the inconsistency. Plasmid primers
did produce small additional peaks in the dissociation curves, but they only produced one
band after agarose gel analysis. Becaue these data were cleaner, the plamid expression was
used as an indicator of cJun over expression.
Using a SYBR-based assay, we were able to determine the trends between
expression of Oct4A, Nanog and Sox2 in relation to the cJun overexpression data. We saw
a slight increase in expression of all genes in cJun transfected samples. The increase in
Oct4A gene expression correlates with Western blot analysis of these samples (Brewer
2018). The increase in Oct4A gene expression is very similar in the transcriptionally
inactive L40/42 samples, which suggests perhaps that the MAPK binding that ocurrs at
those residues to phosphorylate S63 and S73 is not as necessary in this system.
The exon specific primer/probe analyses showed a larger increase in the the Oct4B
variants compared to Oct4A expression, which allowed us to better resolve the isoform
expression differences captured by others in our laboratory who looked at protein
expression. Protein expression was assessed with a polyclonal antibody generated from a
recombinantly produced peptide that contains all amino acids of the human Oct4 protein
that are N-terminal to the POU DNA binding domain. We called Cell Signalling
Technologies to verify this region contains exon 1 of Oct4A as well as amino acids of
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Oct4B. When aligning the human and murine protein sequences, the Oct4B amino acid
sequence is conserved (Figure 13).

A.

B.

Figure 13. The polyclonal antibody used to identify Oct4A has some alignment with
Oct4B. A. A graphical representation of the Oct4B variant transcripts with primers for
exon 1 (red), exon 2 (blue), and exon 5 (green) denoted by F and R. Additional red boxes
outline the approximate position in the protein where the antibody would bind. B.
Alignment of the primary amino acid sequence of the mouse protein with the human
protein up to the POU domain.
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The Oct4 variant specific primer-probe assays reveal a large increase in the cDNA
of Oct4B variants and a decrease in Oct4A. Furthermore, agarose gel electrophoresis reveal
multiple products generated in each of the transfected sample using exon 2 primers. Some
are of expected sizes, as the primers should amplify Oct4b, Oct4b’, Oct4b1, b2, and b3
sequences recently identified by Liu et al (2017), but there are also additional bands. Those
in samples expressing GFP are smaller and not as distinct. The cJun samples have a clearer
band around 400bp and a faint band around 1,00bp. The L40/42 samples analyzed with
primers to both exon 2 and exon 5 appear to have a range of large, distinct bands,
suggesting that loss of phosphorylation of S63/73 affects their expression. One possible
mode of regulation to explain the increase in products specific to L40/42 expression is
through a change in Oct4 mRNA splicing. cJun has previously been shown to particiapte
in splicing regulation by regulating the transcription of several genes involved in the
splicing process. The loss of cJun resulted in a change in splicing pattern for 147 genes,
including 8 involved in cancers and 14 involved in cell death (Katiyar et al. 2012). It would
be interesting to sequence the additional products, which would reveal whether there are
additional variant transcripts that have not been identified or if there is aberrant splicing
occuring, which results in transcripts that differ in intron number and length. Sequencing
would elucidate whether these sequences contain the probe sequence, which would define
which bands contribute to the expression data.
It is also interesting to note that when optimizing the E2 primers, we used cDNA
from embryoid bodies (EBs) because there was little to no product produced from the
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cDNA of untransfected mES cells. Since there are changes in Oct4 expression affected by
cJun over expression, we expect the delicate balance necessary for pluripotency to be
shifted, as levels of 1.5 fold expression are sufficient to affect cell fates (Niwa et al. 2000).
There is some evidence that Oct4B variants may have a function in maintaining
pluripotency as well (Liu et al. 2017). There is a an increase in Sox2 gene expression at a
level that could predict biological significance, as it is highest in cells expressing cJun
L40/42 when compared to cJun wild type. Though these data indicate that cJun may be
regulating Sox2 expression directly by binding the promoter, an alignment analysis of the
Sox2 gene and promoter did not reveal an AP-1 binding site motif; and thus, it is unlikely
that cJun directly regulates Sox2 expression. An alternative model is that it is the increase
of Oct4 by cJun that is responsible for this change, as Oct4 has been shown to regulate
Sox2 expression (Catena et al. 2004).
Even though none of these data were statistically significant, due to large variability
and small sample size, the balance of pluripotency markers is very specific. Less than a
two-fold increase in Oct4 expression can result in the formation of primative endoderm
and mesoderm (Niwa et al. 2000). Sox2 has been shown to repress mesoderm formation
(Wang et al. 2012) and a loss of Nanog results in a failure of the blastocyst inner cell mass
to generate epiblast tissue and ES cells differentiate into extraembryonic endoderm
(Yamaguchi et al. 2005). Additionally, Nanog maintains pluripotency in the absence of
LIF (Yamaguchi et al. 2005).
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cJun Over Expression Directs mESCs Towards an Endoderm Lineage

If slight changes in pluripotency markers have effects on potency, we would predict
that there would be an effect on gene expression of germ layer markers affected by slight
increases in Oct4 expression (Gata4, Gata6) and Sox2, which has been shown to repress
mesoderm formation (Wang et al. 2012) in these cells. Indeed, we observed larger increases
in Gata4 and Gata6 expression of NT normalized data. While the differences were a bit
smaller, GFP normalized data also show the same trend. GFP normalized data showed that
generally an increase in cJun resulted in an increase in Gata4 and Gata6 expression. When
cJun overexpression was at its highest (331.3-fold increase), based on pLVXcJun
amplification, we saw 1.3-fold increase of Gata4 and a 1.2 increase of Gata6. At the lowest
pLVXcJun expression (104.9-fold increase), we saw a decrease in both Gata4 and Gata6
with a 0.75- and 0.79-fold change for Gata4 and Gata6, respectively. The intermediate
overexpression values of 168.5-fold and 190.4-fold resulted in 1.4-fold and 2.4-fold
increase of Gata4, respectively. This corresponded to a 2.6-fold and 1.9-fold increase in in
Gata6, respectively. Western blot analyses performed by others in our laboratory showed
an increase in Gata4 protein in cJun transfected samples as well (Brewer 2018).
Biologically, expression of Gata6 precedes Gata4, as Gata6 drives differentiation to
primitive endoderm and Gata4 marks differentiation into definitive endoderm tissues
(Plusa et al. 2008; Schrode et al. 2013). Additionally, Gata6 is necessary for primitive
endoderm formation, as Gata6 negative ICM cells differentiate into mature epiblast tissue
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prematurely (Schrode et al. 2013). This possibly explains the larger increase in gene
expression for Gata6.
The changes in pluripotency markers seen with overexpression of cJun coupled
with the upregulation of Gata6 suggest cJun could be directing the cells towards endoderm. In addition to these data, cardiomyocytes formed from cJun transfected EBs
exhibited an increased number of beating colonies (Brewer 2018). This supports previous
research that showed Gata4 expression in embryoid bodies directs these cells towards an
endoderm fate, which produce cardiac inducing factors and enhance cardiomyocyte
formation (Holtzinger et al. 2009). This does not exclude the possibility that over
expression of cJun can be initiating the mechanism through other pathways as an increase
in cJun and loss of Oct4 are typically indicators for differentiation.
Other germ layer markers, Brachyury and Sox1, were not as greatly affected by
cJun over expression. When normalized to GFP the mean expression was similar to NT.
Interestingly, Sox1 expression normalized to GFP is greatly affected by L40/42
transfection. Sox1 marks ectodermal lineages and previous data from our lab has shown
that cJun over expression inhibits proper differentiation of pancreatic islet-like insulin
secreting clusters with reduced neural network formation, while the L40/42 transfection
increased both the number of these clusters and the neural projections surrounding them
(Hosawi 2016). The large increase in Sox1 gene expression is supportive of this data and
suggests that a decrease in cJun would direct cells towards ectoderm lineages. Additionally,
Brachyury gene expression was not affected, which correlates with Western blot data that
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did not show any change in protein expression as well (Brewer et al. in prep). This supports
the idea that cJun may not be involved in Brachyury regulation at either the protein or the
transcript level. Taken together, these data indicate that cJun over expression in mES cells
begins directing cells towards an endoderm progam.

Nocodazole-Induced Expression of cJun Produces a Trend of Increased cJun that
Affected the Expression of Pluripotency Genes and Oct4 Variants.

Nocodazole is a cytoskeltal disrupting drug, which can induce alternative tranlation
of mRNA. It has been shown to increase cJun protein levels by intitating translation at an
IRES in the cJun 5’ mRNA in human and rat priamry glia, NIH3T3, HEK293T, Cos-7, and
HeLa cell lines (Polak et al. 2006; Blau et al. 2012). Activation of these mechanisms has
also shown that cJun protein produced in this manner has different downstream effectors
than proteins produced through cap-dependent mechanisms. Our results show nocodazole
treatment of mES cells produced variable expression of cJun. Interestingly, cJun
expression is also affected by DMSO. The mechanism by which DMSO affects cellular
function isn’t fully understood and varies between cell type used. However, it has been
shown it increases differentiation of human embryonic stem cells (hESCs) to definitive
endoderm through the formation of hepatocytes (Pal et al. 2012; Czysz et al. 2015) and
there has been some evidence which suggests that DMSO may affect splice sights in vitro
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(Bolduc et al. 2001). DMSO treatment produced a similar, but less extreme pattern of cJun
variation. Threfore, there is a nocodazole specific increase in cJun expression.
As seen in our transient transection assays, the variations in cJun expression
observed in nocodozole-treated samples associated with variations in gene expression of
Oct4A, Nanog and Sox2 by SYBR analysis. The variation in expression levels observed
between replicates may be due to a dosage affect. The increased expression of Oct4 may
be due to cJun binding the promoter and regulating expression or it may be due to activation
of the IRES present in Oct4. DMSO also produced an increase in Oct4A expression, but
this was complicated by one replicate (replicate 3, table 4) producing an additional band
between 1200bp and 1500bp. This band was not seen in any other sample of the replicate
and could be due to the alternative translation of cJun.
The probe-based assays do not show as great an increase in gene expression,
however the trend holds. Where there is increased cJun due to nocodazole, there is
increased expression of Oct4A (exon 1) and decreased expression of Oct4B (exon 2).
Additionally, extra bands were seen with exon 1 primers at about 250bp and 400bp.
Normalization of all expression data to DMSO maintained the trends seen with NT
normalized data, but indicates cJun expression from nocodazole may affect Oct4
expression in a dose dependent manner. For DMSO normalized data, replicate 1 produces
the highest fold change in expression for cJun at 169.9 and 1.6 for exon 1. Replicate 2
expressed less than half the level of cJun at 43.1, but has a 2.6 fold increase over DMSO
for exon 1. Replicate 3 has the lowest cJun expression at 2.6 and produced a fold change
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of 1.2 for exon 1. These data would indicate that there might be an optimal level of cJun
expression to increase Oct4A, while others promote other Oct4 variants. This would
indicate that cJun regulates Oct4A expression, but does not eliminate the possibility that
nocodazole could regulate protein expression translationally. Western blot analysis was as
variable as the gene expression and requires further study to determine which mechanisms
are functioning in this system.
Gel analysis of the Oct4 primer/probe assays produced similar results to tranfected
data; multiple unexpected bands were seen. Exon 1, which only produced one band for all
treatments in the over expression data, had multiple bands for DMSO- and nocodazoletreated samples. The size of these bands varied between replicate, which is most likely due
to the variable cJun expression. Bands for replicate 1, which had the highest fold change
of 169.9, (Figure 10) are at 250bp and 400bp, while bands for replicate 2, which had a fold
change of 43.1, are only seen in nocodazole samples and are >10,000bp. Additionally
replicate 3 had a fold change of 2.65 and did not produce any extra bands, except a faint
300bp band in one triplicate of nocodazole treated sample. Replicate 4 (data not shown)
showed the most extreme nocodazole response, with extremely bright bands around 500600bp (Appendix D and E) Exon 2 primers produced a large range of bands, similar to
those seen in transfection data and appeared to have a larger variability between replicates.
All replicates had a 350bp band, like the transfected samples; however, this is not an
expected amplicon. Additionally there are many bands between 100-350bp that are also
similar to the transfection data. These regions also encompass the expected amplicon sizes.
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In addition to these similarities, nocodazole samples occasionally produce a 1500bp, or
>10,000bp band that correspond to replicates that show similarly large bands in exon 1.
Interestingly, exon 5 primers show the same trend. The same replicates produce bands
>10,000bp and between 900-1,000bp. In addition to this, NT samples amplified by exon 5
primers occasionally produce bands at 250bp, 300bp, or 400bp. DMSO samples
occassionally have bands at 300bp, while nocodazole samples can have the previously
mentioned large bands or bands at 300bp and 400bp. All of these bands are similar bands
seen with cJun and L40/42 transfected samples, except for the extremely large bands seen
and the additional bands for exon 1, which only produced one band for all transfected
samples. Despite different mechanisms in increasing cJun expression, there appears to be
overlap in the bands produced, indicating the effect on Oct4 variants is the same. The
exceptions to this is the effect on Oct4A and the very large amplicons seen across primer
sets (Appendix D and E)
It is possible that increased cJun from activation of the alternative translation
pathway though nocodazole is affecting the splicing of the Oct4 transcripts such that many
of the introns are not removed. Others have documented a role for cJun in regulation of
splicing events. Studies performed in murine mamary epithilium demonstrate cJun
regulates alternative exon splicing in approximately 147 genes (Katiyar et al. 2011).
Further study of the Oct4 variants and nocodazole is required to ellucidate the effect
alternative translation mechanisms may have on gene expression.
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Given the large changes on Oct4 variants, we would expect the balanced network
of pluripotency factors to be disrupted. While Oct4A expression is increased in nocodazole
samples, the transcript levels may be enough to change potency and begin directing cells
towards a specific fate, much like the spinfection samples. Nanog levels generally
decreased with increased cJun expression and could be due to changes in expression of the
other markers, or as a result of nocodazole treatment directly. Nocodazole has been shown
by flow cytometry to reduce the number of Nanog positive human embryonic stem cells
(Kallas et al. 2011); however they also saw a decrease in Oct4 positive cells. The authors
postulated that nocodazole caused a decrease in Oct4, which decreased Nanog and thus
pluripotency. Discovering how nocodazole affects cJun and the expression of Oct4 variants
may explain this decrease. Sox2 expression did not appear to be affected by nocodazole
treatment. These data would appear to contradict the data produced by overexpression of
cJun through transfection. However, cJun protein produced through alternative translation
may be regulating expression of different genes and no longer regulates expression of Sox2.
It is possible that nocodazole could also be initiating alternative translation of the Oct4
(Guo et al. 2012), which may also have different downstream targets that do not include
Sox2.
Unfortunately, we could not determine the effect of nocodazole on germ layer
expression, as we did with transfection samples, due to an inability to produce EBs in the
presence of nocodazole. The repeated attempts resulted in large amounts of cell death by
day 2. However, because gene expression is a relatively quick process, there may be the
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possibility for a dosing schedule that would reduce cell exposure to the drug and still
initiate a gene expression programs. Further studies will be needed to determine if these
trends in gene expression of pluripotency markers results in a specific differentiation
program. As there are many redundancies in cell signalling and many interconnecting parts
of this system that are still unknown in ES cells, it is difficult to draw any conclusions
beyond the general trends seen.
Nocodozole-Induced Changes in cJun and Oct4 Expression Co-localize to the Same Cells

Nocodazole treatment produced a varied response in protein expression by ICC
analysis as well. The increases in cJun and either Oct4A or Oct4all varied from mild to
large and varied within and between replicates. As each replicate was performed at
different times and with different batches of nocodazole, it is possible the variation is
from that. Despite this, there is a general trend consistant across all replicates. Bright
spots of Oct4A or Oct4all generally co-localize in the same cell as those with high levels
of cJun expression. cJun is not always the brightest at these spots, but it is there. Analysis
of co-localized spots using the Zeiss software supports this trend. Evaluation of colocalization by Pearson’s and Mander’s coefficient shows that 2h nocodazole treatment
produced the strongest cellular co-localization of Oct4A/B with cJun and 4h nocodazole
treatment showed stronger co-localization than NT. However, there were a larger number
of co-localized spots per colony for 4h nocodazole treated samples than 2h nocodazole.
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Previous work demonastrated that nocodazole induces an increase in cJun mRNA
30 minutes post treatment; however, following this, there is no increase in mRNA for the
following 24h in HeLa cells. Despite this, cJun protein increased over 24h (Polak et al.
2006). Our nocodazole samples were harvested 2h post nocodazole treatment and did
show an increase in cJun transcript, which appears to contradict the previous findings.
This could be explained by the transcriptional activity of mES cells, which are in a more
transcriptionally active state. Because of this, mESCs may be more susceptible to gene
expression changes or possibly more sensitive to the cytoskeletal disruption induced by
nocodazole. Additionally, because of the more permissive chromatin structure and
increased cJun, it is possible the increase in cJun cDNA expression seen might be due to
regulation of its own promoter.
The number of cellular co-localization/colony also increased in cells examined
with an antibody recognizing all isoforms of Oct4 (Oct4 all), but the degree of colocalization decreased with nocodazole treatment compared to NT. There was a higher
degree of co-localization with 2h nocodazole samples, compared to 4h treatment. While
the number of co-localized spots did not appear to increase with colony number, colony
size was not taken into account and may be correlated. There appears to be a very
tentative relationship between nocodazole and Oct4A co-localization with cJun versus
Oct4all co-localization with cJun 2h after nocodazole treatment. In this treatment, the
Oct4A/B co-localization increased, while Oct4all co-localization decreased. It is not at all
a definitive relationship, but may indicate a trend that further testing would reveal. It
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would also support the transcriptional data we saw. Generally speaking, there is an
increase in co-localization of Oct4A/B/B1 with cJun in the same cell following
nocodazole treatment, which is supported by transcript data via probe based assays.
Additionally, the inconsistencies seen with ICC and Western blot analysis seem to
correlate with the large variation seen in transcript data.
In addition to co-localization, we observed a few other trends with nocodazole
treatment. While the sub-cellular localization of these proteins cannot be validated on our
microscope, cJun expression appears to be more cytoplasmic 4h after nocodazole
treatment. Oct4all also demonstrated this pattern and cytoplasmic localization of Oct4B
variants has been shown previously with genotoxic, heat, and cell stress (Wang et al.
2009; Gao et al. 2012).
Generally, all co-localized spots had at least a strong Mander’s coefficient. The
Pearson’s coefficient was more distributed from very weak co-localization to very strong.
However, generally very few co-localized spots fell into the weak or very weak category.
This indicates there is a large portion of overlap between these signals in general, but a
more variable correlation in relative signal intensity. Further studies on the effect of
nocodazole on the co-localization of cJun with Oct4 variants could include the use of a
microscopy that images samples in slices, which would help account for the overlap.
Because cell colonies are 3D structures, but our images are not, we cannot determine
whether signal overlap is in the same Z plane. The use of confocal microscopy in
conjunction with deconvolution software and the antibody techniques we utilized could
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improve resolution. Additionally, transmission electron microscopy could be utilized
with stains for specific organelles or structures and gold-labeled anitbodies to identify
these proteins at more precise locations within a single cell.
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CONCLUSIONS

cJun is an important transcription factor in development. Previous work has
shown cJun inhibits expression of genes important to pluripotency, like Sall4 and Nanog,
and upreulates expression of Gata4 and Gata6 (Liu et al. 2015). Generally an increase in
cJun has marked a decrease in pluripotency, but the Oct4 promoter contains an AP-1
binding site that appears to allow cJun regulation of Oct4 variants, including the potency
marker Oct4A.
Through overexpression of cJun by transiently transfecting mES cells, we
determined that cJun may regulate the expression of Oct4 variants, with the strongest
change in Oct4B variants. That we saw a larger increase in these variants with the
transcriptionally inactive L40/42 mutant indicates there may be an alternative splicing
mechanism activated by cJun overexpression. An increase was also seen for Sox2 with
this mutant, indicating a potential mechanism for cJun regulation of Sox2 through Oct4A.
With these samples, we were also able to determine that overexpression of cJun drives
mES cells toward an endoderm lineage and the L40/42 mutant may drive mES cells
towards an ectodermal lineage. The upregulation of Gata4 correlates with cJun
overexpression and the culmination of these data support previous works that show Gata4
expression in EBs increases cardiomyocyte formation by producing specific endoderm
lineages that generate cardiac inducing factors. By using nocodazole to induce cJun
expression we determined that cJun gene expression is increased by drug treatment and
that cJun protein increased by nocodazole co-localizes strongly with Oct4A/B at 2h post
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treatment and not as strongly with other Oct4 variants. More work will be necessary to
determine the exact mechism by which cJun cDNA is increased versus protein
expression using nocodazole stimulation and how that might affect Oct4 gene and protein
expression, as well as potency. Additionally, we were able to determine that additional
bands are produced from Oct4 variants with nocodazole and DMSO that were not seen
with transfected samples. Although more work is required to determine the identity of the
Oct4 variants produced, cJun appears to regulate expression of all Oct4 variants.
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APPENDIX A
Appendix A: Whole electrophoresis gels used in Figure 4, 5, and 8. A. gel of Gapdh
and Sox2 primers amplifying cDNA from mESCs. Gapdh was used in Figure 5, but this
Sox2 set was not used. B. Gel of Nanog and pLVXcJun amplified cDNA used in Figure
5. C. Gel of Sox2 used in Figure 5. D. Gel of Oct4A primers amplifying genomic and
cDNA. E. Gel of Gata4 and Gata6 amplification of cDNA used in Figure 8. Lanes 1, 2,
and 6 are Gata6 and 3, 4, and 5 are Gata4. F. Gel of Sox1 and Brachyury amplification of
cDNA used in Figure 8. G. Gel of cJun amplification of cDNA used in Figure 5. H. Gel
of cJun and pLVXcJun amplification of transfection samples used in Figure 4. I. More
extreme example of multiple bands produced by cJun amplification of transfection
samples. Used in Figure 4.
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APPENDIX B

Appendix B: Primers used for RT-qPCR. The primer name, sequence, expected amplicon size, annealing temperature
used, and qPCR efficiency data, 𝒓𝟐 , slope and efficiency are given. Primers for cJun, Sox2, Nanog, Oct4A (exon 1), and
Oct4all (exon 2 and exon 5) allowed us to assess the effect of cJun overexpression or nocodazole treatment on pluripotency
and endogenous cJun transcription. The pLVXcJun primers allowed us to remove over expressed GFP-cJun mRNA from
endogenous cJun expression in cells transfected with the GFP cJun construct and determine the autoregulatory effects of cJun
on its own gene expression. Gapdh is a constitutively expressed control gene to account for unknown template concentrations.
Brachyury, Gata6, Gata4, and Sox1 expression provided information on whether changes in cJun expression initiate a
differentiation program to a specific germ layer. Efficiencies determined the equation used to analyze the expression data. The
Pffafl equation (2−∆∆𝐶𝑡 ) (Pfaffl 2004) requires that primer efficiencies be equal for the experimental gene as well as the control
gene. The efficiencies below are different and analysis required a variation of the Pffafl equation which accounts for
differences in primer efficiency. Expected base pair values marked with an asterisk denote the probe-based assays which
produced other unexpected bands upon gel analysis.
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Annealing
temp (°C)
60

𝑟2

Slope

Efficiency

Citation

CACCTGTTCCCTGAGCATGTT

Expected
bp
118

0.969737

3.170345

1.067393207

Sprowles
unpublished

cJun-F
Nanog- R

CTCCAAGTGCCGGAAAAGGAA
AGGGTCTGCTACTGAGATGCTCTG

364

61

0.994614

3.466201

0.943122998

(Chen et al. 2012)

Nanog- F
Gapdh-R

CAACCACTGGTTTTTCTGCCACCG
CGAGTTGGGATAGGGCCTCTCTTGC

230

63
61
60

0.902912
0.952598
0.839916

2.874308
2.973768
3.133186

1.227972507
1.169070714
1.085277915

(Chen et al. 2012)

Gapdh-F
Sox2-R

GGTTGTCTCCTGCGACTTCAACAGC
TGCTGCGAGTAGGACATGCTGTAGG

207

63

0.974698

()3.87294

0.812181863

(Chen et al. 2012)

Sox2-F
Oct4A
exon 1-R

GCACATGAACGGCTGGAGCAACG
CCTCCTCTGAGCCCTGT

111bp

60

0.929277
For
SYBR:
0.981957

3.481575
For
SYBR: 3.694379

0.9374313692
For SYBR:
0.8650113822

IDT predesign
qPCR assays

Oct4A
exon 1-F
Oct4A
probe
Oct4all
exon 2-R
Oct4all
exon 2-F
Oct4all
exon 2
probe

AACTGTTCTAGCTCCTTCTGC

91, 296,
297

60

0.945009

3.145305

1.079381572

IDT predesign
qPCR assays

Gene

Sequence 5' to 3'

cJun-R

TGGTTCCACCTTCTCCAACTTCACG
GGTGATCCTCTTCTGCTTCAG
CAGATAGGAACTTGCTGGGT
CTGTTCTAGCTCCTTCTGCAGGGC
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Gene

Sequence 5' to 3'

Oct4all
exon 5-R
Oct4all
exon 5-F
Oct4all
exon 5
probe
pLVX
cJun-R
pLVX
cJun-F
Sox1-R

GTAGCCTCATACTCTTCTCGTTG

𝑟2

Slope

Efficiency

Citation

0.988651

3.209814

1.049012142

IDT predesign
qPCR assays

Expected
bp
135, 274

Annealing
temp (°C)
60

70

61

TTGAGCAGCGTCTTGGTCTTG

134

60

0.9876

3.276507

1.019310351

(Yan et al. 2013)

Sox1-F
BrachyuryR
Brachyury
F
Gata4-R

GCCGAGTGGAAGGTCATGTC
TGCGTCAGTGGTGTGTAATGTG

117

63

0.975551

3.298003

1.010082087

(Bernardo et al.
2011)

ACCAGGCTGTTCCAAGAGTCC

225

63

0.940442

3.264471

1.024549247

(Hu et al. 2013)

Gata4-F
Gata6-R

CAGCAGCAGCAGTGAAGAGATG
GCCAGAGCACACCAAGAATCC

182

63

0.883441

3.733367

0.852911716

(Poh et al. 2014)

Gata6-F

TCTACACAAGCGACCACCTCAG

CCTACAGCAGATCACTCACAT
TCGAACCACATCCTTCTCTAGCCCA

TTGAGGGCATCGTCGTAGAAG

Sprowles
unpublished

CACTAGTGATTGCGGGCC

TCTCTGGTCTGTGAGCAATGGT

111
APPENDIX C

Appendix C: Whole gel images of Oct4 amplification of transfection samples. A. and
B. are gels of exon 1 amplification of spinfection samples for all 4 replicates. C-E. Gels
of exon 2 amplification of transfection samples. F-G. Gels of exon 5 amplification of
transfection samples.
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Appendix D: Whole gel analysis of nocodazole treated samples reveals inconsistency
between replicates. A. Gel of exon 1 amplification of drug treated samples. B. Gel of
exon 5 amplification of drug treated samples. C. Gel of exon 2 amplification of drug
treated samples.
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APPENDIX E

Appendix E: Table of Oct4 predicted bands, additional bands and treatment. This
table highlights some of the variability in Oct4 expression seen with nocodazole
treatment.

Primer set

Expected bands

Bands present

Treatment

Exon 1

1 band-111bp

111bp

All

200bp

Nocodazole

400bp

DMSO

600-700bp

Nocodazole

>10,000

Nocodazole

91bp-possibly
296-297bp
550bp
Multiple 90-250
1,200-1,500bp
>10,000
135bp

All
All
DMSO
All
Nocodazole
Nocodazole
All

274bp

NT and some DMSO

250bp

Some NT

300/350bp

All but inconsistently

400/450bp

Some NT and some
nocodazole

Exon 2

Oct4b’: 91bp
Oct4b2 and 3: 296bp
Oct4b and b1: 297bp

Exon 5

Oct4A, Oct4b’, Oct4b
and Oct4b1: 135bp
Oct4b2 and 3: 274bp

900-1,000bp
>10,000bp

Some nocodazole
Some nocodazole

